 
 
Proprietary and Confidential 
The information in this document is considered privileged and confidential and may not be disclosed to others except 
to the extent necessary to obtain Institutional Review Board approval and infor med consent, or as required by [CONTACT_559400] s tate laws.  Persons to whom this information is disc losed should be informed that this information is privileged 
and confidential and that it should not be further disclosed.  
 
 
CC# 166520: PembroX: Enhancing the Immunogenicity of 
Non- Small Cell Lung Cancer with Pembrolizumab +/ - 
Stereotactic Radiotherapy Delivered in the Preoperative 
Window, A Randomized Phase II Study with Correlative 
Biomarkers 
 
Protocol Number:  CC #166520  
Study Drug: Pembrolizumab  
 
Version Number: 10.0 
Version Date: 03/29/2021 
 
IND Number:  Exempt 
Study ID: [REMOVED]  
 
Principal Investigator (Sponsor- Investigator)   
Sue S. Yom, MD, PhD, MAS  
Helen Diller Family Comprehensive Cancer Center  
University of [LOCATION_004], San Francisco  
  
San Francisco, CA [ZIP_CODE] -1708  
 
 
 
Co-Principle Investigators 
Lawrence Fong, MD, PhD  
Matthew Gubens, MD  
David Jablons,  MD 
 
Statistician  
Ann Lazar, PhD 
  
Revision History
 
Version 2.0  10/04/2016 
Version 3.0  11/20/2016 
Version 4.0  03/07/2017 
Version 5.0  03/23/2017 
Version 6.0  06/01/2017 
Version 7.0  11/15/2017 
Version 8.0  01/16/2018 
Version 9.0  08/08/2018 
Version 10.0  03/29/2021 
 
  

UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 2 of 82   
PROTOCOL SIGNATURE [CONTACT_344536].: 166520 Version Date: 03/29/2021 
 
1. I agree to follow this protocol version as approved by [CONTACT_559401] (PRC), Institutional Review Board (IRB), 
and Data Safety Monitoring Committee (DSMC).  
 
2. I will conduct the study in accordance with applicable IRB requirements, Federal regulations, and state and local laws to maintain the protection of the rights and welfare of study participants.  
 
3. I certify that I, and the study staff, have received the requisite training to conduct this research protocol.  
 
4. I have read and understand the information in the Investigators’ Brochure (or Manufacturer’s Brochure) regarding  the risks and potential benefits. I agree to 
conduct the protocol in accordance with Good Clinical Practices (ICH -GCP), 
the applicable ethical principles, the Statement of Investigator (Form FDA 1572), and with local regulatory requirements. In accordance  with the FDA 
Modernization Act, I will ensure the registration of the trial on the www.clinicaltrials.gov  website.  
 
5. I agree to maintain adequate and accurate records in accordance with IRB policies, Federal, state and local laws and regulations.  
UCSF Principal Investigator / Study Chair  
 
 
Printed Name 
 
 
 
  
[CONTACT_559428]: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 3 of 82  Table of Contents  
PROTOCOL SIGNATURE [CONTACT_1783] ................................................................................. 2  
1.0 TRIAL SUMMARY .............................................................................................. 8  
2.0 TRIAL DESIGN .................................................................................................... 9  
2.1 Trial Design ........................................................................................................ 9  
2.2 Trial Diagram .................................................................................................... 9  
3.0 OBJECTIVES & HYPOTHESES ..................................................................... 11  
3.1 Primary Objectives & Hypotheses ................................................................ 11  
3.2 Secondary Objectives & Hypotheses ............................................................. 11  
3.3 Exploratory Objectives ................................................................................... 12  
4.0 BACKGROUND & RATIONALE .................................................................... [ADDRESS_734761] Population ............................... 17  
4.3.2  Rationale for Dose Selection/Regimen/Modification ................................... 18  
4.3.3  Rationale for SRT Dosing ............................................................................. 19  
4.3.4  Rationale for Endpoints ................................................................................. 20  
4.4 Secondary Objectives & Hypotheses ............................................................. 20  
4.5 Exploratory Objectives ................................................................................... 21  
4.5.1  Biomarker Research ...................................................................................... 21  
5.0 METHODOLOGY .............................................................................................. 21  
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 4 of 82  5.1 Entry Criteria .................................................................................................. 21  
5.1.1  Diagnosis/Condition for Entry into the Trial ................................................ [ADDRESS_734762] Exclusion Criteria ............................................................................. 23  
5.2 Trial Treatments ............................................................................................. 24  
5.2.1  Dose Selection/Modification ......................................................................... 25  
5.2.2  Timing of Dose Administration ...................................................................... 3  
5.2.3  Trial Blinding/Masking ................................................................................... 3  
5.3 Randomization or Treatment Allocation ........................................................ 3  
5.4 Stratification ...................................................................................................... 3  
5.5 Concomitant Medications/Vaccinations (allowed & prohibited) ................. 3  
5.5.1  Acceptable Concomitant Medications ............................................................ 4  
5.5.2  Prohibited Concomitant Medications .............................................................. 4  
5.6 Rescue Medications & Supportive Care ......................................................... 5  
5.6.1  Supportive Care Guidelines ............................................................................ 5  
5.6.2  Pneumonitis: .................................................................................................... 5  
5.6.3  Diarrhea/Colitis: .............................................................................................. 5  
5.6.4  Type 1 diabetes mellitus* ................................................................................ 6  
5.6.5  Hypophysitis: .................................................................................................. 6  
5.6.6  Hyperthyroidism or Hypothyroidism: ............................................................. 6  
5.6.7  Hepatic: ........................................................................................................... 7  
5.6.8  Renal Failure or Nephritis: .............................................................................. 7  
5.7 Diet/Activity/Other Considerations ................................................................. 8  
5.7.1  Diet .................................................................................................................. 8  
5.7.2  Contraception .................................................................................................. 9  
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page [ADDRESS_734763] Withdrawal/Discontinuation Criteria ............................................. [ADDRESS_734764] Replacement Strategy ....................................................................... 11  
5.10  Clinical Criteria for Early Trial Termination .............................................. 11  
6.0 TRIAL FLOW CHART ....................................................................................... 0  
6.1 Study Flow Chart .............................................................................................. 0  
6.2 Trial Procedures ................................................................................................ 2  
6.2.1  Administrative Procedures .............................................................................. 2  
6.2.2  Clinical Procedures/Assessments .................................................................... 4  
6.2.3  Laboratory Procedures/Assessments ............................................................... 6  
6.2.4  Blood Collections ............................................................................................ 7  
6.2.5  Other Procedures ............................................................................................. 7  
6.2.6  Withdrawal/Discontinuation ........................................................................... 8  
6.2.7  Blinding/Unblinding ........................................................................................ [ADDRESS_734765]-Treatment/Safety Follow-Up Visits ........................................................ 9  
6.3 Assessing and Recording Adverse Events ....................................................... 9  
6.3.1  Definitions of Adverse Events ........................................................................ 9  
6.3.2  Recording of an Adverse Event .................................................................... 11  
6.3.3  Follow-up of Adverse Events ........................................................................ 12  
6.3.4  Adverse Events Monitoring .......................................................................... 12  
6.4.5  Expedited Reporting ...................................................................................... 13  
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 6 of 82  6.4.6  Definition of an Overdose for This Protocol and Reporting of Overdose to 
the Principal Investigator [INVESTIGATOR_559380] ........................................................ 15  
6.4.7  Reporting of Pregnancy and Lactation to the Principal Investigator [INVESTIGATOR_559380] ............................................................................................................ 16
 
6.4.8  Immediate Reporting of Adverse Events to the Principal Investigator [INVESTIGATOR_559380] ............................................................................................................ 16
 
[IP_ADDRESS]  Evaluating Adverse Events ........................................................................... [ADDRESS_734766] Approval ........................................................... 25  
9.3 Informed Consent ............................................................................................ 26  
9.4 Changes in the Protocol .................................................................................. 26  
9.5 Handling and Documentation of Clinical Supplies ...................................... 26  
9.6 Case Report Forms (CRFs) ............................................................................ 26  
9.7 Oversight and Monitoring Plan ..................................................................... 27  
9.8 Regulatory Documentation ............................................................................ 27  
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 7 of 82  9.9 Protection of Human Subjects ....................................................................... 28  
9.9.1  Protection from Unnecessary Harm .............................................................. 28  
9.9.2  Protection of Privacy ..................................................................................... 28  
10.0  REFERENCES .................................................................................................... 29  
APPENDIX 1  ECOG Performance Status ................................................................. 32  
APPENDIX 2  Common Terminology Criteria for Adverse Events V4.0 (CTCAE)
 33  
APPENDIX 3  Response  Evaluation  Criteria  in  Solid  Tumors  (RECIST)  1.1  
Criteria  for Evaluating Response in Solid Tumors ......................................... 34  
APPENDIX 4  UCSF Policy/Procedure for Required Regulatory Documents for 
Single Site and Multicenter Investigator-Initiated Oncology Clinical Trials 35  
APPENDIX 5  Data and Safety Monitoring Plan for a Phase II or III Institutional 
Trial  40  
 
  
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 8 of 82  1.0 TRIAL SUMMARY 
 
Abbreviated Title  PembroX  
Trial Phase  II 
Clinical Indication  Non-small cell lung cancer, resectable  
Trial Type  Randomized phase II  
Type of control  Control arm of randomized schema  
Route of administration  Intravenous  
Trial Blinding  No 
Treatment Groups  (1) Pembrolizumab followed by [CONTACT_44850] (2) Stereotactic radiation 
therapy and pembrolizumab followed by [CONTACT_559402]  40 
Estimated enrollment period  9 months: 4 patients per month  
Estimated duration of trial  25 months  
Duration of Participation  15 months  
Estimated  average  length  of 
treatment per patient 3 months, 12 months follow -up 
 
  
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 9 of 82  2.0 TRIAL DESIGN 
2.1 Trial Design 
This is a randomized single-institution, phase II, open-label clinical trial of neoadjuvant 
pembrolizumab with or without low-dose stereotactic radiation therapy (SRT) in stage I- IIIA 
non-small lung cancer (NSCLC) patients who are planned to undergo surgical resection of their 
lung cancer. 
Two consecutive run-in cohorts will administer pembrolizumab or pembrolizumab with SRT of 
[ADDRESS_734767] allowable amount of delay. 
If during the run-in, only the pembrolizumab-alone cohort meets pre-specified safety parameters, 
subsequently enrolled patients will enter a larger expansion cohort, with treatment given 
according to that cohort only. If during the run-in both cohorts meet pre- specified safety 
parameters, subsequently enrolled patients will enter the expansion cohort and be randomized 
between preoperative pembrolizumab versus pembrolizumab with SRT of 12 Gy. 
Patients will be followed every 12 weeks for 1 year for disease status and survival. 
2.2 Trial Diagram 
Two consecutive run-in cohorts will be treated establishing the safety of neoadjuvant 
pembrolizumab and pembrolizumab-SRT delivered in the preoperative window. An expansion 
cohort will include a larger number of patients who will be treated with pembrolizumab alone or 
be randomized between the two arms. 
Cohort 1: [ADDRESS_734768] dose of pembrolizumab. If ≤33% of patients experience grade 3 immune-related toxicity attributable to study 
interventions (as determined within 30 days of date of surgery), or £ 1 patient progresses to 
unresectability over the course of study treatment, proceed to Cohort 2. 
If >33% of patients experience grade 3 immune-related toxicity attributable to study 
interventions (as determined within 30 days of date of surgery), or > 1 patient progresses to unresectability over the course of study treatment, the study will terminate. 
Cohort 2: 6 patients. The patients will undergo 2 cycles of pembrolizumab then within the week 
(7 days +/- 3 days) following administration of the second cycle, a single fraction of SRT (12 
Gy) will be delivered to 50% of the primary tumor only. Definitive surgical resection will occur 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page [ADDRESS_734769] dose of pembrolizumab. 
If ≤33% of patients experience grade 3 immune-related toxicity attributable to study 
interventions (as determined within 30 days of date of surgery), or £ 1 patient progresses to 
unresectability over the course of study treatment, proceed to Expansion Cohort (randomization 
between parameters of Cohort 1 and Cohort 2, e.g. randomization between preoperative pembrolizumab versus pembrolizumab and SRT). 
If >33% of patients in Cohort 2 experience grade 3 immune-related toxicity attributable to study 
interventions (as determined within 30 days of date of surgery), or > 1 patient progresses to 
unresectability over the course of study treatment, then proceed to Expansion Cohort (parameters only of Cohort 1, e.g. preoperative pembrolizumab alone). 
Expansion Cohort: [ADDRESS_734770] dose of pembrolizumab. 
Stoppi[INVESTIGATOR_10020]: If at any point during the study, >15% of patients progress to unresectability 
over the course of the study treatment, then the study will terminate. This stoppi[INVESTIGATOR_559381], for all patients enrolled in any phase 
of the protocol. Each case of study-induced medical unfitness, tumor progression, or any other 
cause resulting in unresectability will trigger a re-evaluation of the 15% stoppi[INVESTIGATOR_1877]. 
 
* Cycle 2 of pembrolizumab should be given except as recommended per protocol, section [IP_ADDRESS]. 
** SRT is delivered within 7 days +/- 3 days of second pembrolizumab cycle. If second cycle is 
not given due to discontinuation, SRT should not be given (patient should continue to surgery 

UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 11 of 82  when deemed safe by [CONTACT_559403]). 
^ Surgery will take place no later than [ADDRESS_734771] dose of pembrolizumab, e.g. no 
later than week 7 if only one cycle of pembrolizumab was tolerated, or if two cycles of pembrolizumab were given, week 10. 
# Adjuvant blood collection will take place at follow-up visits (30d, 90d, 180d and 360d (+14d) 
after surgery). 
Adjuvant therapy such as systemic therapy +/- radiation therapy following surgery will be 
administered according to the standard of care per judgment of the treating physician(s). 
3.0 OBJECTIVES & HYPOTHESES 
3.1 Primary Objectives & Hypotheses  
(1) Objective: To determine the change in the number of infiltrating CD3+ T cells/ μm 2 in the lung 
cancer tissue between the paired biopsy and thoracotomy specimens, as quantified by 
[CONTACT_9064] (IHC) and image analysis. 
Hypothesis: For resectable NSCLC, the administration of pembrolizumab +/- low-dose 
stereotactic SRT in the preoperative window will enhance tumor immunogenicity, resulting in two-fold greater infiltrating CD3+ T cells/ μm
2 in the primary and/or regional environment at the 
time of surgical resection, as compared to the time of initial biopsy. 
3.2 Secondary Objectives & Hypotheses 
(1) Objective: To assess the safety of preoperative pembrolizumab +/- SRT when combined 
with surgery; 
Hypothesis: In patients scheduled for NSCLC resection, pembrolizumab, or pembrolizumab 
+ SRT, given in the preoperative window, will meet safety criteria described by [CONTACT_760]; 
(2) Objective: To record the toxicity of preoperative pembrolizumab +/- SRT when combined 
with surgery, according to CTCAE v. 4, including immune-related adverse events (AEs); 
Hypothesis: In patients scheduled for NSCLC resection, pembrolizumab, or pembrolizumab 
+ SRT, given in the preoperative window, will result in acceptable short-term and perioperative toxicity; 
(3) Objective:  To  determine  the  1-year  overall  survival  rate  resulting  from  
preoperative pembrolizumab +/- SRT when combined with surgery; 
Hypothesis: In patients scheduled for NSCLC resection, pembrolizumab + SRT given in the 
preoperative window will result in a higher 1-year survival rate than pembrolizumab alone; 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 12 of 82  (4) Objective: To determine the 1-year relapse free survival rate resulting from preoperative 
pembrolizumab +/- SRT when combined with surgery; 
Hypothesis: In patients scheduled for NSCLC resection, pembrolizumab + SRT given in the 
preoperative window will result in a higher 1-year relapse free survival rate than 
pembrolizumab alone; 
(5) Objective: To determine the 1-year rate of distant metastases resulting from preoperative 
pembrolizumab +/- SRT when combined with surgery; 
Hypothesis: In patients scheduled for NSCLC resection, pembrolizumab + SRT given in the 
preoperative window will result in a lower 1-year distant metastasis rate than pembrolizumab 
alone; 
(6) Objective: To assess quality of life associated with preoperative pembrolizumab +/- SRT when 
combined with surgery; 
Hypothesis: In patients scheduled for NSCLC resection, pembrolizumab, or pembrolizumab + SRT, given in the preoperative window, will result in acceptable short-term and perioperative quality of life; 
(7) Objective: To determine the rate of unresectability that results from a program of preoperative pembrolizumab +/- SRT to be followed by a planned surgery; 
Hypothesis: In patients scheduled for NSCLC resection, either pembrolizumab or pembrolizumab + SRT given in the preoperative window will both result in <15% overall rate of unresectability following the preoperative progra m; 
3.3 Exploratory Objectives 
(1) Objective: To determine the difference in the number of infiltrating T cell subsets (cytotoxic 
CD8+, helper CD4+ FOXP3-, and regulatory CD4+ FOXP3+ T cells) between the biopsy and 
the surgery specimens, as quantified by [CONTACT_559404]; 
Hypothesis: Preoperative pembrolizumab +/- SRT will produce quantitatively detectable 
changes in the infiltrating T cell subsets as compared to pre-treatment biopsy; 
(2) Objective: To determine the change in the intratumoral T-cell repertoire by [CONTACT_559405]-cell T-cell profiling; 
Hypothesis: Preoperative pembrolizumab +/- SRT will produce quantitatively detectable changes in the intratumoral T-cell repertoire as compared to pre-treatment specimens; 
(3) Objective: To quantify treatment-induced changes in the circulating T cell immune response 
using TCR sequencing and enzyme-linked immunospot (ELISPOT) assays; 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 13 of 82  Hypothesis: Preoperative pembrolizumab +/- SRT will produce quantitatively detectable 
changes in the circulating T cell immune response as compared to pre-treatment specimens; 
4.0 BACKGROUND & RATIONALE 
4.1 Background 
Refer to the Investigator’s Brochure (IB)/approved labeling for detailed background information on MK-3475. 
4.1.[ADDRESS_734772] immune surveillance in controlling outgrowth of  neoplastic 
transformation has been known for decades. Accumulating evidence shows a correlation between 
tumor-infiltrating lymphocytes (TILs) in cancer tissue and favorable prognosis in various 
malignancies. In particular, the presence of CD8+ T-cells and the ratio of CD8+ effector T-cells / 
FoxP3+ regulatory T-cells seems to correlate with improved prognosis and long-term survival in 
many solid tumors. 
The PD-[ADDRESS_734773] hijacked by [CONTACT_13207]. The normal function of PD-1, expressed on the cell surface of activated T-cells under 
healthy conditions, is to down-modulate unwanted or excessive immune responses, including 
autoimmune reactions. PD-1 (encoded by [CONTACT_13228]1) is an Ig superfamily member related to 
CD28 and CTLA-4 which has been shown to negatively regulate antigen receptor signaling upon 
engagement of its ligands (PD-L1 and/or PD-L2). The structure of murine PD-1 has been resolved. 
PD-1 and family members are type I transmembrane glycoproteins containing an Ig Variable-type 
(V-type) domain responsible for ligand binding and a cytoplasmic tail which is responsible for the 
binding of signaling molecules. The cytoplasmic tail of PD-1 contains 2 tyrosine-based signaling 
motifs,  an  immunoreceptor  tyrosine-based  inhibition  motif  (ITIM)  and  an  immunoreceptor 
tyrosine-based switch motif (ITSM). Following T-cell stimulation, PD-[ADDRESS_734774] from that of CTLA-4 as both molecules regulate an overlappi[INVESTIGATOR_178863]. PD-1 was shown to be expressed on activated lymphocytes including peripheral CD4+ and CD8+ T-cells, B-cells, T regs and Natural Killer cells. Expression has also 
been shown during thymic development on CD4-CD8- (double negative) T-cells as well as subsets 
of macrophages and dendritic cells. The ligands for PD-1 (PD-L1 and PD-L2) are constitutively 
expressed or can be induced in a variety of cell types, including non-hematopoietic tissues as well 
as in various tumors. Both ligands are type I transmembrane receptors containing both IgV- and 
IgC-like domains in the extracellular region and contain short cytoplasmic regions with no known 
signaling motifs. Binding of either PD-[ADDRESS_734775] 
notably on vascular endothelium, whereas PD-L2 protein is only detectably expressed on antigen- 
presenting cells found  in lymphoid tissue  or chronic inflammatory environments. PD-L2  is 
thought to control immune T-cell activation in lymphoid organs, whereas PD-L1 serves to dampen 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 14 of 82  unwarranted T-cell function in peripheral tissues. Although healthy organs express little (if any) 
PD-L1, a variety of cancers were demonstrated to express abundant levels of this T-cell inhibitor. 
PD-1 has been suggested to regulate tumor-specific T-cell expansion in subjects with melanoma 
(MEL). This suggests that the PD-1/PD-L1 pathway plays a critical role in tumor immune evasion and should be considered as an attractive target for therapeutic intervention. 
Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the 
IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD- 
L1 and PD-L2. Keytruda
TM (pembrolizumab) has recently been approved in the [LOCATION_002] for 
the treatment of patients with unresectable or metastatic melanoma and disease progression following ipi[INVESTIGATOR_164], if BRAF V600 mutation positive, a BRAF inhibitor. 
4.1.[ADDRESS_734776]-in-human phase I study showed that pembrolizumab was well tolerated at doses of up to 
10 mg/kg every 2 weeks and demonstrated evidence of antitumor activity in multiple tumor types including melanoma, Merkel cell carcinoma, and NSCLC (Patnaik 2015). Based on these data, 
pembrolizumab was first approved in September 2014 by [CONTACT_559406][INVESTIGATOR_164] a BRAF 
inhibitor, in patients who were BRAF V600 mutation—positive (Robert 2014). In October 2015, 
the FDA granted accelerated approval for pembrolizumab to treat patients with advanced or 
metastatic NSCLC whose disease progressed after other treatments and with tumors that express PD-L1 based on the results of the KEYNOTE-001 trial (Garon 2015). 
KEYNOTE -[ADDRESS_734777] 1 dose of pembrolizumab. Overall, 50% of patients were 
male with a median age of 64 (range, 28–93) and most had good Eastern Cooperative Oncology 
Group (ECOG) performance statuses of 0 or 1. Among 495 patients, about 80% had non-squamous 
histology and had previously received more than two lines of chemotherapy. Patients were treated 
with pembrolizumab alone at a dose of either 2 mg/kg every 3 weeks (Q3 W) ( n = 6), or 10 mg/kg 
Q3 W (n = 287), or 10 mg every 2 weeks (Q2 W) (n = 202) (Garon 2015). Across patients 
regardless of dose, schedule, histology, and history of smoking, the overall response rate (ORR) 
was 19.4% [95% confidence interval (CI), 16.0–23.2] by [CONTACT_119549] (RECIST) v1.1. ORR was 18.0% [95% CI, 14.4–22.2] for 394 patients previously treated 
and 24.8% [95% CI, 16.7–34.3] for [ADDRESS_734778] overall response for 108 (21.8%) patients. Pembrolizumab demonstrated a response rate of 33.3% [95% CI, 4.3–77.7] at 2 mg/kg Q3 W, 19.2% [95% CI, 14.8–24.2] at 10 mg/kg Q3 W, 
and 19.3% [95% CI, 14.1–25.4] at 10 mg/kg Q2 W. Patients with squamous histology (n = 85) 
showed an ORR of 23.5% [95% CI, 15.0–34.0] and the ORR for patients with non-squamous 
histology was 18.7% [95% CI, 15.0–22.9]. Smoking status influenced ORR (10.3% for never smokers vs. 22.5% for former/current smokers). Notably, the median duration of response was 
12.5 months (range, 1.0–23.3) for all patients, 10.4 months (range, 1.0–10.4) for previously treated 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 15 of 82  patients, and 23.3 months (range, 1.0–23.3) in treatment-naïve patients. At the data collection 
cutoff (August 2014), the median duration of PFS was 3.7 months [95% CI, 2.9–4.1] in all patients 
(3.0 months [95% CI, 2.2–4.0] in previously treated patients, and 6.0 months [95% CI, 4.1–8.6] in 
treatment-naïve patients), and the median duration of OS was 12.0 months [95% CI, 9.3–14.7] in 
all patients (9.3 months [95% CI, 8.4–12.4] for previously treated patients and 16.2 months [95% 
CI, 16.2—not reached] for previously untreated patients) (Garon 2015). For adverse events (AEs) 
considered to be treatment related, fatigue, pruritus, and decreased appetite were the most common 
AEs and occurred in 10–20% of all patients. There was no clear difference between the incidence 
of AEs and the dose/schedule of pembrolizumab. AEs of grade 3 or higher were reported in 47 of 
495 patients (9.5%). Immune-related AEs occurred in ≥2% of patients including hypothyroidis m 
(n = 34, 6.9%), hyperthyroidism (n = 9, 1.8%), infusion-related reaction (n = 10, 2%), and 
pneumonitis (n = 18, 3.6%). There was a single case of grade 5 interstitial lung disease that resulted 
in death (Garon 2015). 
KEYNOTE -010 
The pi[INVESTIGATOR_559382]/III randomized KEYNOTE-010 trial compared the effects of pembrolizumab 
and docetaxel in patients with previously treated NSCLC ([STUDY_ID_REMOVED]). From August 2013 to 
April 2015, this international, open-label study randomized 1034 patients with PD-L1 positive 
NSCLC to the FDA-approved dose of 2 mg/kg of pembrolizumab, an elevated dose of 10 mg/kg 
of PD-1 inhibitor, or 75 mg/m 2 of docetaxel. All three regimens were administered at 3-week 
intervals. All patients had progressed following platinum-based chemotherapy and eligible patients expressed PD-L1 on >1% of their tumor cells, and predefined subgroup analysis will be performed for those of strongly PD-L1-positive patients, defined as those expressing PD-L1 on 
≥50% of their tumor cells. The primary endpoint was OS and secondary endpoint was PFS. Tumor 
response was measured by [CONTACT_393] 1.1 at week 12, and then every 6 weeks thereafter. Promising 
results were recently published (Herbst 2016). Pembrolizumab improved overall survival versus 
docetaxel in both standard and higher-dose arms (median 14.9 and 17.3 months with 2 mg/kg and 
10 mg/kg of pembrolizumab, respectively and 8.2 months with docetaxel), as well as in the overall 
study population and in the strongly PD-L1-positive subgroup. Hazard ratio (HR) for OS of 0.54 
[95% CI, 0.38–0.77] and 0.50 [95% CI, 0.36–0.70] for the two dosing schedules of pembrolizumab 
(at 2 mg/kg and 10 mg/kg, respectively) was noted for the patients with the highest biomarker 
expression  (tumor  proportion  score,  TPS  ≥  50%)  as  compared  to  docetaxel.  Interestingly, 
pembrolizumab also demonstrated a benefit in OS for patients in the total study population (>1% 
PD-L1 positivity in the tumor was required at study entry), with hazard ratios of 0.71 [95% CI, 
0.58–0. 88] and 0.61 [95% CI, 0.49–0.75] in the pembrolizumab arms at 2 mg/kg and 10 mg/kg, 
respectively. PFS also significantly improved with both dosing schedules of pembrolizumab 
versus chemotherapy in high PD-L1 expressers (median 5.0 and 5.2 vs. 4.1 months). Based on the 
promising efficacy of pembrolizumab in previously treated NSCLC, several clinical trials of 
pembrolizumab as first-line therapy or adjuvant therapy for NSCLC after curative resection are currently underway. 
KEYNOTE -042 
Based on the promising results especially chemo-naïve NSCLC patients from early clinical trial, 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page [ADDRESS_734779]-line therapy. KEYNOTE-042 trial (ClinicalTrial.gov, 
[STUDY_ID_REMOVED]), a randomized, open-label phase I trial will evaluate the efficacy and safety of 
pembrolizumab vs. platinum doublet chemotherapy as first-line therapy for PDL-1 positive 
advanced NSCLC. Eligible patients with advanced PDL-1 positive NSCLC without EGFR 
mutations or ALK translocation and ≥1 measurable lesion will be randomized 1:1 to 
pembrolizumab 200 mg every 3 weeks or investigator’s choice of carboplatin plus paclitaxel or 
carboplatin plus pemetrexed (Mok 2015). Patients will be stratified by [CONTACT_76678] (0 vs. 1), 
histology (squamous vs. non-squamous),  region (East Asia vs. non-East Asia), and  PDL-1 
expression (strong vs. weak [staining in ≥50% vs. 1–49% of tumor cells assessed by 
[CONTACT_559407] 22C3 antibody]). Primary end point is overall survival in patients 
with PDL-1 strongly positive tumors and secondary endpoints include progression-free survival in 
strongly positive patients and PFS and OS in all patients.  
4.2 PD-L1 expression by [CONTACT_559408] a companion diagnostic, the PD-L1 
immunohistochemistry (IHC) 22C3 pharmDx test, the first test designed to detect PD-L1 
expression in NSCLC. The clinical trial assay was developed by [CONTACT_69726], an in vitro diagnostic 
manufacturer. In the KEYNOTE-001 trial, the overall prevalence of PD-L1 expression ≥1% was 60.8% among 824 patients including 58.6% of the 643 previously treated patients and 68.5% of 
the 181 previously untreated patients. The prevalence of a proportion score (PS) of at least 50% 
was 24.9% among previously untreated patients and 22.7% among previously treated patients 
(Garon 2015). Notably, the ORR (45.2% vs. 16.5% vs. 10.7%), PFS (6.4 vs. 4.1 vs. 4.0 months), 
and OS (not reached vs. 10.6 vs. 10.4 months) were significantly higher for patients whose tumors 
expressed PD-L1 membranous staining ≥50% compared to patients with a PS of 1–49% or those 
with a score less than 1%. A cutoff of ≥50% PD-L1 positivity in tumor cell membranes was 
determined as optimal by [CONTACT_399912] (ROC) analysis. In contrast, PD-L1 
expression was not associated with predictive markers of any efficacy endpoints in the Checkmate 
017 study with nivolumab, in which patients with pretreated squamous NSCLC were compared 
with those treated with docetaxel (Brahmer 2015). There was a favorable trend of unstratified 
hazard ratios toward nivolumab in patients with higher PD-L1 expression (≥10%, ≥5%, and ≥1%) 
and similar rates of objective response were observed among patients with PD-L1 positive tumors 
and those with PD-L1 negative tumors. On the other hand, another trial of nivolumab in pretreated 
advanced non-squamous NSCLC (Checkmate 057) compared with docetaxel demonstrated a 
meaningful separation of the overall survival curves across all pre-specified PD-L1 expression levels (at ≥1%, ≥5%, and ≥10%) (Borghaei 2015). However, PD-L1 expression in both studies 
was evaluated retrospectively in pretreatment (archival or recent) tumor biopsy specimens using 
rabbit monoclonal antihuman PD-L1 antibody (clone 28-8, Epi[INVESTIGATOR_559383]). In a phase I study of anti- 
PD-L1 antibody MPDL3280A, PD-L1 was stained with an antihuman PD-L1 rabbit monoclonal 
antibody (clone SP142, Ventana) and PD-L1 expression was evaluated on both tumor cells and 
tumor-infiltrating immune cells. While the association of response to MPDL3280A treatment and 
tumor-infiltrating immune (TIL) cell PD-L1 expression was significant, the association with tumor 
cell PD-L1 expression was not (Herbst 2014). 
Recent pooled sensitive analyses of phase I–III clinical trials of PD-1/PD-L1 inhibitors 
(nivolumab, pembrolizumab, or MPDL3280A) including 511 NSCLC patients showed that 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 17 of 82  patients with PD-L1 positive tumor achieved significantly more responses than PD-L1-negative 
patients (23.2% vs. 14.5%), with an absolute difference of 8.7% (95% CI 1.1–15.5) (Carbognin 
2015). However, the use of PD-L1 IHC positivity as a predictive marker remains controversial in 
the context of different anti-PD-L1 antibodies, staining techniques, definitions of positive tumor 
cells or immune cells, tumor site (primary vs. metastasis), tumor type (archival vs. recent), and 
various cutoffs. 
4.[ADDRESS_734780] Population 
We hypothesize that neoadjuvant treatment with pembrolizumab and targeted stereotactic 
radiation therapy (SRT) will improve patients’ immunogenic responses during and after surgical 
treatment of their non-small cell lung cancer. The timing of the interventions during the 
neoadjuvant phase will allow us to perform comprehensive analyses on tumor specimens before 
any treatment and after initial response to pembrolizumab alone or pembrolizumab with SRT. 
In this study, patients are offered immunotherapy +/- SRT before surgery but are free to pursue 
chemotherapy +/- external beam radiation therapy after surgery. It is important to call attention  
to this deliberate aspect of the study design, which ends protocol-mandated treatment at the time 
of surgery, such that patients are allowed to pursue postoperative treatment appropriate to their 
surgical/pathologic stage. While chemotherapy is considered part of the perioperative standard of 
care for NSCLC patients undergoing resection, the only available randomized evidence showed 
no statistical difference in long-term disease-free survival, whether chemotherapy was 
administered preoperatively or postoperatively (Felip 2010). Thus, neoadjuvant chemotherapy 
given prior to surgery is not considered a standard of care, and in fact the extremely well 
established standard of care is to offer postoperative chemotherapy +/- radiotherapy depending 
on the pathologic outcome at surgery, as advocated by [CONTACT_559409] (McElnay 2014). Likewise, there is no clear 
benefit to external beam radiotherapy whether given preoperatively or postoperatively. In 
addition, emerging recent evidence indicates that in several different tumor types, cisplatin may 
stimulate upregulation of PD-L1 and that this could be associated with subsequent cisplatin 
resistance (Zhang 2016, Mesnage 2016, Yan 2016). Therefore, the rationale for administration of 
immunotherapy prior to administration of cisplatin, with the possibility of inducing a durable 
immune response prior to surgery and expected postoperative therapy, may offer a more 
therapeutically effective strategy. 
Furthermore, our thoracic surgery service has extensive experience performing operations on 
patients who are currently receiving immunotherapy for a variety of malignancies, and thus far 
there have been no issues with delays due to therapy. It is expected that the amount of delay of 
surgery will be relatively minimal, even accounting for administration of 1-2 cycles of 
pembrolizumab. Given the relatively poor outcomes for NSCLC, even among patients who are 
eligible for definitive surgical resection, novel approaches to treating this population are greatly 
needed. 
The strategy offered in this study will allow us to define a rationale for therapi[INVESTIGATOR_3508], when 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page [ADDRESS_734781]-line setting, could result in more complete 
and durable responses for patients. The study design will allow us to investigate intratumoral and 
circulating immunologic changes as a result of preoperative therapy, as well as potential 
mechanisms of synergy between pembrolizumab and stereotactic radiation therapy in addressing local-regional and distant disease recurrence.
 
4.3.2 Rationale for Dose Selection/Regimen/Modification  
An open-label Phase I trial (Protocol 001) is being conducted to evaluate the safety and clinical 
activity of single agent MK-3475. The dose escalation portion of this trial evaluated three dose 
levels, 1 mg/kg, 3 mg/kg, and 10 mg/kg, administered every 2 weeks (Q2W) in subjects with 
advanced solid tumors. All three dose levels were well tolerated, and no dose-limiting toxicities 
were observed. This first in human study of MK-3475 showed evidence of target engagement 
and objective evidence of tumor size reduction at all dose levels (1 mg/kg, 3 mg/kg and 10  
mg/kg Q2W). No MTD has been identified to date. 10.0 mg/kg Q2W, the highest dose tested in PN001, was utilized in Cohorts A, B, C and D of this protocol to test for initial tumor activity. 
Recent data from other clinical studies within the MK-3475 program has shown that a lower 
dose of MK-3475 and a less frequent schedule may be sufficient for target engagement and 
clinical activity. 
PK data analysis of MK-3475 administered Q2W and Q3W showed slow systemic clearance, 
limited volume of distribution, and a long half-life (refer to IB). Pharmacodynamic data (IL-2 
release assay) suggested that peripheral target engagement is durable (>21 days). This early PK 
and pharmacodynamic data provide scientific rationale for testing a Q2W and Q3W dosing 
schedule. 
A population pharmacokinetic analysis has been performed using serum concentration time data 
from [ADDRESS_734782] a wide therapeutic range based on the melanoma 
indication. The differences in exposure for a 200 mg fixed dose regimen relative to a 2 mg/kg 
Q3W body weight-based regimen are anticipated to remain well within the established exposure 
margins of 0.5 – 5.0 for MK-3475 in the melanoma indication. The exposure margins are based 
on the notion of similar efficacy and safety in melanoma at 10 mg/kg Q3W vs. the proposed dose 
regimen of 2 mg/kg Q3W (i.e. 5-fold higher dose and exposure). The population PK evaluation 
revealed that there was no significant impact of tumor burden on exposure. In addition, exposure 
was similar between the NSCLC and melanoma indications. Therefore, there are no anticipated changes in exposure between different indication settings. 
The rationale for further exploration of 2 mg/kg and comparable doses of pembrolizumab in solid 
tumors is based on: 1) similar efficacy and safety of pembrolizumab when dosed at either 2 mg/kg 
or 10 mg/kg Q3W in melanoma patients, 2) the flat exposure-response relationships of pembrolizumab for both efficacy and safety in the dose ranges of 2 mg/kg Q3W to 10 mg/kg Q3W, 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 19 of 82  3) the lack of effect of tumor burden or indication on distribution behavior of pembrolizumab (as 
assessed by [CONTACT_78013]) and 4) the assumption that the dynamics of pembrolizumab target engagement will not vary meaningfully with tumor type. 
The choice of the 200 mg Q3W as an appropriate dose for the switch to fixed dosing is based on 
simulations performed using the population PK model of pembrolizumab showing that the fixed 
dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent with those 
obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient exposures in the 
exposure range established in melanoma as associated with maximal efficacy response and 3) will 
maintain individual patients exposure in the exposure range established in melanoma that are well tolerated and safe. 
A fixed dose regimen will simplify the dosing regimen to be more convenient for physicians and 
to reduce potential for dosing errors. A fixed dosing scheme will also reduce complexity in the logistical chain at treatment facilities and reduce wastage. 
4.3.[ADDRESS_734783] immune-mediated antitumor effects of radiotherapy (Verbrugge 2012). Anti-CD137 
therapy significantly enhanced radiotherapy-induced tumor control, but the response was short- 
lived. The addition of anti-PD-1 antibody to anti-CD137 antibody and radiation led to cures at 
the primary irradiated tumor site, while anti-PD1 monotherapy was not very effective. After 
testing of various radiation regimens, they found that 12 Gy x 1 fraction led to 100% cure, 
whereas the cure rates with 5 Gy x 4 fractions and 4 Gy x 5 fractions were 80% and 40%, respectively. 
Zeng et al. found that a radiation regimen of 12 Gy x 1 fraction, when combined with anti-PD-1 
antibody, led to long-term survival in a mouse glioma model whereas neither therapy by [CONTACT_559410] 
(Zeng 2013). The combination therapy was associated with increased infiltration by [CONTACT_28746] T 
cells and decreased regulatory T cells within the tumor microenvironment. Deng et al. also used 
this radiation regimen (12 Gy x 1 fraction) and anti-PD- L1 therapy to show synergistic inhibition 
of TUBO mammary carcinoma and MC38 colon adenocarcinoma growth in mice (Deng 2014). 
Furthermore, they showed that PD-L1 expression was upregulated in tumor cells after radiotherapy 
and that radiation and anti-PD-L1 led to a synergistic reduction in the local accumulation of tumor-
infiltrating myeloid-derived suppressor cells that normally suppress T cell function within the tumor microenvironment. 
Twyman-Saint Victor et al. conducted preclinical studies using both anti-CTLA4 and anti-PD-1 
(or PD-L1) therapy and radiation (Twyman-Saint Victor 2015). B16- F10 melanoma tumors 
were grown in the bilateral flanks of mice. Tumor in one flank was irradiated (20 Gy) and 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 20 of 82  growth was assessed in both the irradiated and the unirradiated tumors. Mice were treated with 
anti-CTLA4 antibody, anti PD-1/PD-L1 antibody or both prior to and after irradiation. In these 
experiments, the addition of radiation to anti-CTLA4 improved responses in irradiated and 
unirradiated tumors; however, resistance was common. Integrated genomic and immune  
profiling revealed that resistance was due to upregulation of PD-L1 on melanoma cells and 
associated with T cell dysfunction, known as exhaustion. Even in the presence of dual  
checkpoint blockade, omission of radiation resulted in high rates of relapse. Investigation into 
how each treatment impacted mechanisms that influence response revealed that anti-CTLA4 
predominantly inhibits regulatory T cells (Treg) to increase the CD8+ T cell to Treg (CD8/Treg) 
ratio, radiation enhances the diversity of the T cell receptor repertoire of intratumoral T cells, and 
anti- PD-L1 reverses T cell exhaustion. Together, dual checkpoint blockade promotes expansion 
of T cells, while radiation shapes the T cell receptor repertoire of the expanded peripheral clones. 
Many ongoing studies at present are testing comparisons between various single-fraction doses 
versus more fractionated regimens in combination with immunomodulatory compounds. At least 
based on available data from in vivo studies delivering radiation in combination with CTLA-[ADDRESS_734784] but also very likely to be safe. Partial SRT (irradiation wil l 
be prescribed to approximately 50% of the primary tumor) will be given to avoid CD4+ and CD8+ T cell depletion within the irradiated primary tumor and allow for the assessment of local effects resulting from reshapi[INVESTIGATOR_559384] T cell repertoir e. 
4.3.4 Rationale for Endpoints
 
The primary endpoint for this study is the change in number of infiltrating CD3+ T cells/ μm 2 in 
the lung cancer tissue from before and after pembrolizumab +/- SRT, based on quantification using 
immunohistochemistry (IHC) and image analysis. This endpoint was selected as a marker of T cell 
proliferation and activation. It is expected that immunologic activation would be reflected by [CONTACT_559411]. The purpose of this study is to determine whether neoadjuvant 
pembrolizumab +/- SRT is sufficient to produce a two-fold change in the CD3+ T cell population, comparing pre-treatment biopsy tissue to post-treatment resection specimens. 
Despi[INVESTIGATOR_559385], 
a large percentage will succumb to regional or distant metastatic disease manifestation. Therefore, 
this study will also include exploratory objectives aimed at the possibility of a potential 
improvement in 1-year clinical outcomes from the addition of neoadjuvant immune modulation. 
4.4 Secondary Objectives & Hypotheses 
Secondary objectives include safety according to criteria described by [CONTACT_760] (≤33% grade  
3 immune-related toxicity); toxicity according to CTCAE v. 4, including immune-related adverse events (AEs); and quality of life. 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page [ADDRESS_734785] overall clinical benefits and merit further study.  
4.5 Exploratory Objectives 
4.5.1 Biomarker Research 
PD-L1 expression will be tested in tumor specimens to investigate correlations to immune 
response from treatment with pembrolizumab. 
Other exploratory objectives will further describe immune changes resulting from neoadjuvant 
pembrolizumab +/- SRT. These will include: changes in the number of infiltrating T cell subsets; 
change in the intratumoral T-cell repertoire by [CONTACT_559412]-cell T-cell profiling; 
and treatment-induced changes in the circulating T cell immune response using TCR sequencing and enzyme-linked immunospot (ELISPOT) assays. 
5.0 METHODOLOGY 
5.1 Entry Criteria 
5.1.1 Diagnosis/Condition for Entry into the Trial  
1. Histologically or cytologically confirmed non-small cell lung cancer, performed on a 
biopsy that occurred within the last [ADDRESS_734786]  75 days showing radiographic stage I to IIIa lung cancer 
(mediastinal staging biopsy is allowed but not required). 
3. Documentation that the patient is a candidate for surgical resection of their lung cancer by [CONTACT_559413]-certified surgeon. 
4. Measurable disease as defined by [CONTACT_393] v1.1. 
5. Adequate tissue specimens for correlative biomarker analysis. The patient should be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 120 days prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Principal Investigator. 
6. Eastern Cooperative Oncology Group (ECOG) performance status of [ADDRESS_734787]: 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 22 of 82  1. Be willing and able to provide written informed consent/assent for the trial. 
2. Be ³ 18 years of age on day of signing informed consent. 
3. Demonstrate adequate organ function as defined in Table 1. All screening labs should 
be performed within 10 days of treatment initiation, unless specified below. 
Table 1 Adequate Organ Function Laboratory Values 
System  Laboratory Value  
Hematological   
Absolute neutrophil count (ANC)  ≥1,500 /mcL  
Platelets  ≥100,000 / mcL  
Hemoglobin a ≥9 g/dL or ≥5.6 mmol/L  
Renal   
Serum creatinine OR 
Measured or calculated b creatinine clearance  
(GFR can also be used in place of creatinine or CrCl)  ≤1.5 X upper limit of normal (ULN) OR 
 
≥60 mL/min for subject with creatinine levels > 1.[ADDRESS_734788] 
Hepatic   
Serum total bilirubin  ≤ 1.[ADDRESS_734789] (SGOT) and ALT (SGPT)  ≤ 2.[ADDRESS_734790]  
Coagulation  
International Normalized Ratio (INR) or Prothrombin 
Time (PT)  
 
Activated Partial Thromboplastin Time (aPTT) ≤1.[ADDRESS_734791] is receiving anticoagulant therapy  as long 
as PT or PTT is within therapeutic range of intended use of anticoagulants  
≤1.[ADDRESS_734792] received transfusion or erythropoietin (EPO) within 7 days of the hemoglobin (Hgb) lab  
test as this may artificially inflate the Hgb lab value.  
bCreatinine clearance should be calculated per institutional standard.  
4. Female subject of childbearing potential should have a negative urine or serum 
pregnancy within [ADDRESS_734793] will be required. 
5. Female subjects of childbearing potential (Section 5.7.2) must be willing to use an 
adequate method of contraception, as outlined in Section 5.7.2 – Contraception, for the 
course of the study through [ADDRESS_734794] dose of study medication. 
Note: Abstinence is acceptable if this is the usual lifestyle and preferred 
contraception for the subject. 
6. Male subjects of childbearing potential (Section 5.7.1) must agree to use an adequate 
method of contraception as outlined in Section 5.7.1- Contraception, starting with the first dose of study therapy through [ADDRESS_734795] dose of study therapy. 
Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject. 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page [ADDRESS_734796]: 
1. Is ineligible for an operation based on medical or oncologic contraindications to 
surgery. 
2. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required 
steroids or has current pneumonitis/interstitial lung disease. 
3. Has evidence of interstitial lung disease. 
4. Has an active second malignancy, i.e. patient known to have potentially fatal cancer present for which he/she may be (but not necessarily) currently receiving treatment. 
Patients with a history of malignancy that has been completely treated, with no 
evidence of that cancer currently, are permitted to enroll in the trial if curative therapy 
has been completed, such as basal cell carcinoma of the skin or squamous cell 
carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. 
5. Is currently participating and receiving study therapy or has participated in a study of 
an investigational agent and received study therapy or used an investigational device 
within [ADDRESS_734797] dose of trial treatment. 
7. Has a known history of active TB (Bacillus Tuberculosis) 
8. Hypersensitivity to pembrolizumab or any of its excipi[INVESTIGATOR_840]. 
9. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study 
Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due 
to agents administered more than 4 weeks earlier. 
10. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy 
within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. 
- Note:  Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study. 
- Note: If subject received major surgery, they must have recovered 
adequately from the toxicity and/or complications from the intervention 
prior to starting therapy. 
11. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or 
immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or 
physiologic corticosteroid replacement therapy for adrenal or pi[INVESTIGATOR_13002], etc.) is not considered a form of systemic treatment. 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page [ADDRESS_734798]’s 
participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opi[INVESTIGATOR_80021]. 
14. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 
15. Is pregnant or  breastfeeding, or expecting  to conceive  or  father children within 
the projected duration of the trial, starting with the pre-screening or screening 
visit through [ADDRESS_734799] dose of trial treatment. 
16. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent. 
17. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 
antibodies). 
18. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected). 
19. Has received a live vaccine or live-attenuated vaccine within [ADDRESS_734800] dose of the study drug. Administration of killed vaccines is allowed. 
Note: Seasonal influenza vaccines for injection are generally inactivated flu 
vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) 
are live attenuated vaccines, and are not allowed.  
5.2 Trial Treatments 
The treatment to be used in this trial is outlined below in Table 2.  
Table 2 Trial Treatment 
Drug  Dose/Potency  Dose 
Frequenc
y Route of 
Administratio
n Regimen/Trea
t- ment 
Period  Use 
Pembrolizumab  200 mg  Q3W  IV infusion  Day 1 of each 
3-week  cycle Experimental  
Stereotactic radiation therapy will be given at a prescription dosage of 12 Gy at the 80% isodose 
line, to be delivered in one single treatment session in one day, to 50% +/- 10% of the primary 
tumor volume, as determined by [CONTACT_559414] (PTV). The lateral half of the 
tumor should be encompassed within the PTV and the medial aspect of the tumor relative to the 
patient should not be included in the PTV. Treatment may be delivered from either a linear 
accelerator or robotic SRT delivery system. SRT, if the patient is to receive it according to the 
terms of the protocol, should be given within 7 days (+/- 3 days) following the second 
administration of pembrolizumab. If the second cycle is not given, then SRT should not be given. 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 25 of 82  During dose expansion, trial treatment should begin on the day of randomization or as close as 
possible to the date on which treatment is allocated/assigned. 
5.2.1 Dose Selection/Modification  
[IP_ADDRESS] Dose Selection 
The rationale for selection of doses to be used in this trial is provided in Section 4.0 – Background 
and Rationale. 
Details on preparation and administration of pembrolizumab (MK-3475) are provided in the 
Pharmacy Manual.  
[IP_ADDRESS]  Dose Modification (Escalation/Titration/Other)  
Adverse events (both non-serious and serious) associated with pembrolizumab exposure, 
including coadministration with additional compounds, may represent an immunologic etiology. 
These adverse events may occur shortly after the first dose or several months after the last dose 
of pembrolizumab/combination and may affect more than one body system simultaneously.. 
Pembrolizumab/combination treatment must be withheld for drug-related toxicities and severe or 
life-threatening AEs as per Table 3 below. See Section 5.6 for supportive care guidelines, 
including use of corticosteroids. 
If a patient continues to experience toxicity, or if dosing with study drug is interrupted for > [ADDRESS_734801] to potential toxicity. Toxicity 
will be assessed according to the NCI Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0). 
Attribution of Toxicity: 
When study interventions are administered in combination, attribution of an adverse event to a 
single component is likely to be difficult.  Therefore, while the investigator may attribute a toxicity event to the combination, to stereotactic radiotherapy, or to pembrolizumab alone, for adverse events listed in Table 3, both interventions must be held according to the criteria in Table 3 Dose Modification and Toxicity Management Guidelines for Immune-Related Adverse Events Associated with Pembrolizumab. 
Holding Study Interventions: 
When study interventions are administered in combination, if the AE is considered immune-
related, both interventions should be held according to recommended dose modifications. 
Restarting Study Interventions: 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page [ADDRESS_734802] any dose modifications (no change in dose or schedule) of 
pembrolizumab in this study, as described in Table 3. 
• If the toxicity does not resolve or the criteria for resuming treatment are not met, the participant must be discontinued from all study interventions. 
If the toxicities do resolve and conditions are aligned with what is defined in Table 3, the combination of stereotactic radiotherapy and pembrolizumab may be restarted at the discretion of the investigator. In these cases where the toxicity is attributed to the combination or to stereotactic radiotherapy alone, re-initiation of pembrolizumab as a monotherapy may be considered at the principal investigator’s discretion.
  
UCSF Helen Diller Family Comprehensive Cancer Center  
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 0 of 82  Table 3 Dose Modification and Toxicity Management Guidelines for Immune-Related AEs associated with pembrolizumab 
monotherapy and IO Combinations 
General instructions:  
1. Severe and life -threatening irAEs should be treated with IV corticosteroids followed by [CONTACT_13215]. Other immunosuppressive treatment should begin if irAEs are not 
controlled by [CONTACT_13216].  
2. Study intervention must be permanently discontinued if the irAE does not resolve or the corticosteroid dose is not ≤10 mg/day  within [ADDRESS_734803] study 
intervention treatment.  
3. The c orticosteroid taper should begin when the ir AE is < Grade [ADDRESS_734804] 4 weeks.  
4. If study intervention has been withheld, study intervention may resume after the irAE decreased to < Grade [ADDRESS_734805] eroid taper.  
irAEs Toxicity Grade (CTCAE  
v5.0) Action with  pembrolizumab  Corticosteroid and/or other 
therapi[INVESTIGATOR_178869] -up 
Pneumonitis  Grade 2  Withhold  • Administer corticosteroids 
(initial dose of 1 to 2 mg/kg prednisone or equivalent) followed by [CONTACT_13217]  
• Add prophylactic antibiotics 
for opportunistic infections  • Monitor participants for signs 
and symptoms of pneumonitis  
• Evaluate participants with suspected pneumonitis with radiographic imaging and initiate 
corticosteroid treatment  Recurrent Grade 2, Grade 3 
or 4 Permanently discontinue  
Diarrhea/Colitis  Grade 2 or 3  Withhold  • Administer corticosteroids 
(initial dose of 1 to 2 mg/kg prednisone or equivalent) followed by [CONTACT_13217]  • Monitor participants for signs 
and symptoms of enterocolitis (i.e., diarrhea, abdominal pain, blood or mucus in stool with or 
without fever) and of bowel 
perforation (i.e., peritoneal signs 
and ileus) 
• Participants with ≥Grade 2 diarrhea suspecting colitis should consider GI consultation and performing endoscopy to rule out colitis  
• Participants with diarrhea/colitis should be advised to drink liberal quantities of clear fluids. If sufficient oral fluid intake is not 
feasible, fluid and electrolytes 
should be substituted via IV 
infusion  Recurrent Grade [ADDRESS_734806] or ALT 
Elevation or Increased Bilirubin
 Grade 2 a Withhold  • Administer corticosteroids 
(initial dose of 0.5 to 1 
mg/kg prednisone or • Monitor with liver function tests 
(consider weekly or more 
frequently until liver enzyme 
UCSF Helen Diller Family Comprehensive Cancer Center  
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 1 of 82  equivalent) followed by 
[CONTACT_78014]) 
Grade 3 b or 4 c Permanently discontinue  • Administer corticosteroids 
(initial dose of 1 to 2 mg/kg prednisone or equivalent) 
followed by [CONTACT_13217]  
T1DM or 
Hyperglycemia  New onset T1DM or Grade 
3 or 4 hyperglycemia associated with evidence of 
b-cell failure  Withhold d • Initiate insulin replacement 
therapy for participants with T1DM  
• Administer antihyperglycemic in participants with 
hyperglycemia  • Monitor participants for 
hyperglycemia or other signs and symptoms of diabetes  
Hypophysitis  Grade 2  Withhold  • Administer corticosteroids 
and initiate hormonal 
replacements as clinically 
indicated  • Monitor for signs and symptoms 
of hypophysitis (including 
hypopi[INVESTIGATOR_19341])  Grade 3 or 4  Withhold or permanently 
discontinue d 
Hyperthyroidism  Grade 2  Continue  • Treat with nonselective 
beta- blockers ( e.g., 
propranolol) or thionamides 
as appropriate  • Monitor for signs and symptoms 
of thyroid disorders.  Grade 3 or 4  Withhold or permanently 
discontinue1 
Hypothyroidism  Grade 2 -4 Continue  • Initiate thyroid replacement 
hormones ( e.g., 
levothyroxine or liothyroinine) per standard 
of care  • Monitor for signs and symptoms 
of thyroid disorders.  
Nephritis : grading 
according to 
increased 
creatinine or acute 
kidney injury  Grade 2  Withhold  • Administer corticosteroids 
(prednisone 1  to 2 mg/kg or 
equivalent) followed by [CONTACT_13217]. • Monitor changes of renal function  
Grade 3 or 4  Permanently discontinue  
Neurological 
Toxicities  Grade 2  Withhold  • Based on severity of AE 
administer corticosteroids  • Ensure adequate evaluation to 
confirm etiology and/or exclude 
other causes  Grade 3 or 4  Permanently discontinue  
Myocarditis  Grade 1 or 2  Withhold  • Based on severity of AE 
administer corticosteroids  • Ensure adequate evaluation to 
confirm etiology and/or exclude 
other causes  Grade 3 or 4  Permanently discontinue  
Exfoliative Suspected SJS, TEN, or Withhold  
UCSF Helen Diller Family Comprehensive Cancer Center  
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – pembrolizumab +/ - stereotactic radiotherapy   Page 2 of 82  Dermatologic 
Conditions  DRESS  • Based on severity of AE 
administer corticosteroids  • Ensure adequate evaluation to 
confirm etiology or exclude other 
causes  Confirmed SJS, TEN, or 
DRESS  Permanently discontinue  
All other irAEs  persistent Grade 2  Withhold  • Based on severity of AE , 
administer corticosteroids  • Ensure adequate evaluation to 
confirm etiology and/or exclude other causes  Grade 3  Withhold or discontinue 
based on the evente. 
Events that require discontinuation include and not limited to: Gullain -Barre Syndrome, 
encephalitis  
recurrent Grade 3  or Grade 
4 Permanently discontinue  
AE(s)=adverse event(s); ALT= alanine aminotransferase; AST=aspartate aminotransferase; CTCAE=Common Terminology Criteria for Adverse Events; 
DRESS=Drug Rash with Eosinophilia and Systemic Symptom; GI=gastrointestinal; IO=immuno -oncology; ir=immune related; IV=intravenous; SJS=Stevens -
Johnson Syndrome; T1DM=type 1 diabetes mellitus; TEN=Toxic Epi[INVESTIGATOR_19342]; ULN=upper limit of normal.  
Note : Non -irAE will be managed as appropriate, following clinical practice recommendations.  
a  AST/ALT: >3.[ADDRESS_734807] if baseline normal; >3.0 to 5.0 x baseline, if baseline abnormal;  
bilirubin:>1.[ADDRESS_734808] if baseline normal; >1.[ADDRESS_734809]/ALT: >5.[ADDRESS_734810], if baseline normal; >5.0 to 20.0 x basel ine, if baseline abnormal; bilirubin:>3.[ADDRESS_734811] if baseline normal; >3.[ADDRESS_734812]/ALT: >20.[ADDRESS_734813], if baseline normal; >20.0 x baseline, if baseline abnormal;  
bilirubin:  >10.[ADDRESS_734814] if baseline normal; >10.0 x  baseline if baseline abnormal  
d The decision to withhold or permanently discontinue pembrolizumab is at the discretion of the investigator or treating physic ian. If control achieved or ≤  Grade 
2, pembrolizumab may be resumed.  
e Events that require discont inuation include, but are not limited to: encephalitis and other clinically important irAEs.  
1. Withhold or permanently discontinue pembrolizumab is at the discretion of the investigator or treating physician.  
NOTE: For participants with Grade 3 or 4 immune -related endocrinopathy where withhold of pembrolizumab is required, pembrolizumab may 
be resumed when AE resolves to ≤ Grade 2 and is controlled with hormonal replacement therapy or achieved metabolic control (in case of T1DM).  
 
UCSF Helen Diller Family Comprehensive Cancer Center  
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 3 of 82  Dosing interruptions are permitted in the case of medical / surgical events or logistical reasons not 
related to study therapy (e.g., elective surgery, unrelated medical events, patient vacation, and/or 
holidays). Subjects should be placed back on study therapy within 3 weeks of the scheduled 
interruption, unless otherwise discussed with the Principal Investigator. The reason for interruption 
should be documented in the patient's study record.  
5.2.2 Timing of Dose Administration  
Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments 
have been completed as detailed on the Trial Flow Chart (Section 6.0). Trial treatment may b e 
administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative 
reasons. 
All trial treatments will be administered on an outpatient basis. 
Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks, for 2 
cycles. Sites should make every effort to target infusion timing to be as close to 30 minutes as 
possible. However, given the variability of infusion pumps from site to site, a window of -5 
minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min). 
The Pharmacy Manual contains specific instructions for the preparation of the pembrolizumab 
infusion fluid and administration of infusion solution. 
5.2.3 Trial Blinding/Masking  
This trial is open label; therefore, the subject, the trial site personnel, the Principal Investigator 
[INVESTIGATOR_1238]/or designee are not blinded to treatment. 
5.3 Randomization or Treatment Allocation 
For the run-in cohorts, consecutive patients will be enrolled. 
In the expansion cohort, consecutive patients will be enrolled if only Cohort 1 conditions are 
fulfilled. If Cohort 1 and Cohort 2 both meet safety criteria, then patients will be enrolled in the Expansion Cohort using permuted-block randomization with block size of 4. 
5.4 Stratification 
No stratification is to be performed. 
5.5 Concomitant Medications/Vaccinations (allowed & prohibited) 
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed during the ongoing trial. If there is a clinical indication for one of these or other medications or 
UCSF Helen Diller Family Comprehensive Cancer Center  
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 4 of 82  vaccinations specifically prohibited during the trial, discontinuation from trial therapy or 
vaccination may be required. The investigator should discuss any questions regarding this with the 
Principal Investigator. The final decision on any supportive therapy or vaccination rests with the 
treating investigator and/or the subject's primary physician. 
5.5.[ADDRESS_734815]’s welfare may be administered 
at the discretion of the investigator in keepi[INVESTIGATOR_77981]. All 
concomitant medication will be recorded on the case report form (CRF) including all prescription, 
over the counter (OTC), herbal supplements, and IV medications and fluids. If changes occur 
during the trial period, documentation of drug dosage, frequency, route, and date may also be 
included on the CRF. 
All concomitant medications received within [ADDRESS_734816] dose of trial treatment should be recorded for SAEs and 
ECIs as defined in Section 7.2. 
5.5.2 Prohibited Concomitant Medications  
Subjects are prohibited from receiving the following therapi[INVESTIGATOR_43837]: 
• Antineoplastic systemic chemotherapy or biological therapy 
• Immunotherapy not specified in this protocol 
• Investigational agents other than pembrolizumab 
• Radiation therapy outside of that prescribed per protocol 
• Live vaccines within [ADDRESS_734817] dose of trial treatment and while 
participating in the trial. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, 
BCG, and typhoid vaccine. 
• Systemic glucocorticoids for any purpose other than to modulate symptoms from 
an event of clinical interest of suspected immunologic etiology. The use of 
physiologic doses of corticosteroids may be approved after consultation with the Principal Investigator. 
Subjects who, in the assessment by [CONTACT_093], require the use of any of the aforementioned 
treatments for clinical management should be removed from the trial. Subjects may receive other 
medications that the investigator deems to be medically necessary. 
The Exclusion Criteria describes other medications which are prohibited in this trial. There are 
UCSF Helen Diller Family Comprehensive Cancer Center  
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page [ADDRESS_734818]-Treatment Follow-up Phase. 
5.6 Rescue Medications & Supportive Care 
5.6.1 Supportive Care Guidelines  
Subjects should receive appropriate supportive care measures as deemed necessary by [CONTACT_124133]. Suggested supportive care measures for the management of adverse events with 
potential immunologic etiology are outlined below. Where appropriate, these guidelines include 
the use of oral or intravenous treatment with corticosteroids as well as additional anti-inflammatory 
agents if symptoms do not improve with administration of corticosteroids. Note that several 
courses of steroid tapering may be necessary as symptoms may worsen when the steroid dose is 
decreased. For each disorder, attempts should be made to rule out other causes such as metastati c 
disease or bacterial or viral infection, which might require additional supportive care. The treatment guidelines are intended to be applied when the investigator determines the events to be 
related to pembrolizumab. 
Note: if after the evaluation the event is determined not to be related, the investigator does not 
need to follow the treatment guidance (as outlined below). Refer to Section 5.2.1 for dose 
modification. 
It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or skin 
photography as part of evaluation of the event. 
5.6.2 Pneumonitis
: 
[IP_ADDRESS] For Grade 2 events, treat with systemic corticosteroids. When symptoms improve to 
Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. 
[IP_ADDRESS] For Grade 3-4 events, immediately treat with intravenous steroids. Administer additional 
anti-inflammatory measures, as needed. 
[IP_ADDRESS] Add prophylactic antibiotics for opportunistic infections in the case of prolonged steroid 
administration . 
5.6.3 Diarrhea/Colitis : 
Subjects should be carefully monitored for signs and symptoms of enterocolitis (such as diarrhea, abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such as peritoneal signs and ileus). 
[IP_ADDRESS] All  subjects  who  experience  diarrhea/colitis  should  be  advised  to  drink  liberal quantities of clear fluids.  If sufficient oral fluid intake is not feasible, fluid and 
electrolytes should be substituted via IV infusion. For Grade 2 or higher diarrhea, consider 
UCSF Helen Diller Family Comprehensive Cancer Center  
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 6 of 82  GI consultation and endoscopy to confirm or rule out colitis. 
[IP_ADDRESS] For Grade 2 diarrhea/colitis, administer oral corticosteroids. 
[IP_ADDRESS] For Grade 3 or 4 diarrhea/colitis, treat with intravenous steroids followed by [CONTACT_180731]. 
[IP_ADDRESS] When symptoms improve to Grade 1 or less, steroid taper should be started and continued 
over no less than 4 weeks. 
5.6.4 Type 1 diabetes mellitus*  
*(if new onset, including diabetic ketoacidosis [DKA]) or ≥ Grade 3 Hyperglycemia, if 
associated with ketosis (ketonuria) or metabolic acidosis (DKA) 
[IP_ADDRESS] For T1DM or Grade 3-4 Hyperglycemia 
[IP_ADDRESS].1 Insulin replacement therapy is recommended for  Type I diabetes mellitus and 
for Grade 3-4 hyperglycemia associated with metabolic acidosis or ketonuria. 
[IP_ADDRESS].2 Evaluate patients with serum glucose and a metabolic panel, urine ketones, glycosylated hemoglobin, and C-peptide. 
5.6.5 Hypophysitis : 
[IP_ADDRESS] For Grade 2 events, treat with corticosteroids. When symptoms improve to Grade 1 or 
less, steroid taper should be started and continued over no less than 4 weeks. Replacement 
of appropriate hormones may be required as the steroid dose is tapered. 
[IP_ADDRESS] For Grade 3-4 events, treat with an initial dose of IV corticosteroids followed by [CONTACT_79918]. When symptoms improve to Grade 1 or less,  steroid  taper should be 
started and continued over no less than 4 weeks. Replacement of appropriate hormones 
may be required as the steroid dose is tapered. 
5.6.6 Hyperthyroidism or Hypothyroidism : 
Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid 
function (at the start of treatment, periodically during treatment, and as indicated based on clinical 
evaluation) and for clinical signs and symptoms of thyroid disorders. 
[IP_ADDRESS] Grade 2 hyperthyroidism events (and Grade 2-4 hypothyroidism): 
[IP_ADDRESS].1 In  hyperthyroidism,  non-selective  beta-blockers  (e.g.  propranolol)  are 
suggested as initial therapy. 
[IP_ADDRESS].[ADDRESS_734819] of care. 
[IP_ADDRESS] Grade 3-4 hyperthyroidism 
[IP_ADDRESS].1 Treat  with  an  initial  dose  of  IV  corticosteroid  followed  by  [CONTACT_78019]. When symptoms improve to Grade 1 or less, steroid taper 
should be started and continued over no less than 4 weeks. 
Replacement of appropriate hormones may be required as the 
UCSF Helen Diller Family Comprehensive Cancer Center  
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 7 of 82  steroid dose is tapered. 
5.6.7 Hepatic : 
[IP_ADDRESS] For Grade 2 events, monitor liver function tests more frequently until 
returned to baseline values (consider weekly). 
[IP_ADDRESS].1 Treat with IV or oral corticosteroids 
[IP_ADDRESS] For Grade 3-4 events, treat with intravenous corticosteroids for 24 to 48 
hours. 
[IP_ADDRESS] When symptoms improve to Grade 1 or less, a steroid taper should be 
started and continued over no less than 4 weeks. 
5.6.8 Renal Failure or Nephritis : 
[IP_ADDRESS] For Grade 2 events, treat with corticosteroids.  
o For Grade 3- 4 events, treat with systemic corticosteroids.  
o When symptoms improve to Grade 1 or less, steroid taper should be started 
and continued over no less than 4 weeks.  
5.6.9 Management of Infusion Reactions: Signs and symptoms usually develop 
during or shortly after drug infusion and generally resolve completely within 24 
hours of completion of infusion. 
Table 3 below shows treatment guidelines for subjects who experience an 
infusion reaction associated with administration of pembrolizumab (MK-
3475). 
 
UCSF Helen Diller Family Comprehensive Cancer Center  
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 8 of 82  Table 3 Infusion Reaction Treatment Guidelines 
NCI CTCAE Grade  Treatment  Premedication at subsequent dosing  
Grade 1  
Mild reaction; infusion interruption not 
indicated; intervention not indicated  Increase monitoring of vital signs as medically indicated until 
the subject is deemed medically stable in the opi[INVESTIGATOR_871].  None  
Grade 2  
Requires infusion interruption but 
responds promptly to symptomatic 
treatment (e.g., antihistamines, 
NSAIDS, narcotics, IV fluids); prophylactic medications indicated for  
< =24 hrs  Stop Infusion and monitor symptoms. Additional appropriate 
medical therapy may include but is not limited to:  
IV fluids Antihistamines NSAIDS  
Acetaminophen Narcotics  
Increase monitoring of vital signs as medically indicated until 
the subject is deemed medically stable in the opi[INVESTIGATOR_1070].  
If symptoms resolve within one hour of stoppi[INVESTIGATOR_13056], the infusion may be restarted at 50% of the original infusion 
rate (e.g., from 100 mL/hr to 50 mL/hr). Otherwise dosing will 
be held until symptoms resolve and the subject should be premedicated for the next scheduled dose. 
Subjects who develop Grade [ADDRESS_734820] may be 
premedicated 1.5h (± 30 
minutes) prior to infusion of 
pembrolizumab (MK -3475) 
with:  
Diphenhydramine 50  mg po  (or equivalent dose of 
antihistamine).  
Acetaminophen 500 -1000 
mg po (or equivalent dose of antipyretic).  
Grades 3 or 4  Stop Infusion.  No subsequent dosing 
Grade 3:  
Prolonged (i.e., not rapi[INVESTIGATOR_77984]/or brief 
interruption of infusion); recurrence of 
symptoms following initial improvement; hospi[INVESTIGATOR_12197] (e.g., renal 
impairment, pulmonary  Additional appropriate medical therapy may include but is not 
limited to: 
IV fluids Antihistamines NSAIDS  
Acetaminophen Narcotics Oxygen   
infiltrates)  
Grade 4:  
Life-threatening; pressor or ventilatory 
support indicated Pressors Corticosteroids Epi[INVESTIGATOR_559386].  
Hospi[INVESTIGATOR_13021].  
Subject is permanently discontinued from further trial treatment administration.   
Appropriate resuscitation equipment should be available in the room and a physician readily available during the period of dr ug 
administration.  
5.7 Diet/Activity/Other Considerations 
5.7.1 Diet 
Subjects should maintain a normal diet unless modifications are required to manage an AE such 
as diarrhea, nausea or vomiting. 
UCSF Helen Diller Family Comprehensive Cancer Center  
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page [ADDRESS_734821] 
azoospermia (whether due to having had a vasectomy or due to an underlying medical condition). 
Female subjects will be considered of non-reproductive potential if they are either: 
(1) postmenopausal (defined as at least 12 months with no menses without an alternative 
medical cause; in women < 45 years of age a high follicle stimulating hormone (FSH) 
level in the postmenopausal range may be used to confirm a post-menopausal state in 
women not using hormonal contraception or hormonal replacement therapy. In the absence 
of 12 months of amenorrhea, a single FSH measurement is insufficient.); 
OR 
(2) have had a hysterectomy and/or bilateral oophorectomy, bilateral salpi[INVESTIGATOR_139595]/occlusion, at least 6 weeks prior to screening; 
OR 
(3) has a congenital or acquired condition that prevents childbearing. 
Female and male subjects of reproductive potential must agree to avoid becoming pregnant 
or impregnating a partner, respectively, while receiving study drug and for [ADDRESS_734822] dose of study drug by [CONTACT_139649]: 
(1) practice abstinence
† from heterosexual activity; OR 
(2) use (or have their partner use) acceptable contraception during heterosexual activity. Acceptable methods of contraception are
‡: 
Single method (one of the following is acceptable): 
• intrauterine device (IUD) 
• vasectomy of a female subject’s male partner 
• contraceptive rod implanted into the skin  
Combination method (requires use of two of the following): 
• diaphragm with spermicide (cannot be used in conjunction with cervical 
cap/spermicide) 
• cervical cap with spermicide (nulliparous women only) 
• contraceptive sponge (nulliparous women only) 
UCSF Helen Diller Family Comprehensive Cancer Center  
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 10 of 82  • male condom or female condom (cannot be used together) 
• hormonal contraceptive: oral contraceptive pi[INVESTIGATOR_4382] (estrogen/progestin pi[INVESTIGATOR_401115]-only pi[INVESTIGATOR_4382]), contraceptive skin patch, vaginal contraceptive ring, or 
subcutaneous contraceptive injection 
†Abstinence (relative to heterosexual activity) can be used as the sole method of 
contraception if it is consistently employed as the subject’s preferred and usual 
lifestyle and if considered acceptable by [CONTACT_176742]/IRBs. 
Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation 
methods, etc.) and withdrawal are not acceptable methods of contraception. 
‡If a contraceptive method listed above is restricted by [CONTACT_427]/guidelines, 
then it does not qualify as an acceptable method of contraception for subjects 
participating at sites in this country/region. 
Subjects should be informed that taking the study medication may involve unknown risks to the 
fetus (unborn baby) if pregnancy were to occur during the study. In order to participate in the study 
subjects of childbearing potential must adhere to the contraception requirement (described above) 
from the day of study medication initiation (or 14 days prior to the initiation of study medication 
for oral contraception) throughout the study period up to [ADDRESS_734823]’s status until the pregnancy has been completed or terminated. The outcome 
of the pregnancy will be reported to the Principal Investigator [INVESTIGATOR_559387] 24 hours to the Principal Investigator [INVESTIGATOR_295760] 2 working days to [COMPANY_006] if the outcome 
is a serious adverse experience (e.g., death, abortion, congenital anomaly, or other disabling or 
life-threatening complication to the mother or newborn). 
The study investigator will make every effort to obtain permission to follow the outcome of the 
pregnancy and report the condition of the fetus or newborn to the Principal Investigator. If a male 
subject impregnates his female partner the study personnel at the site must be informed 
immediately and the pregnancy reported to the Principal Investigator [INVESTIGATOR_559388] 7.2.2.
 
5.7.[ADDRESS_734824]-feeding are not eligible for enrollment.  
UCSF Helen Diller Family Comprehensive Cancer Center  
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page [ADDRESS_734825] Withdrawal/Discontinuation Criteria 
Subjects may withdraw consent at any time for any reason or be dropped from the trial at the 
discretion of the investigator should any untoward effect occur. In addition, a subject may be 
withdrawn by [CONTACT_559415] [INVESTIGATOR_559389], the trial plan is violated, or for administrative and/or other safety reasons. Specific details regarding discontinuation or withdrawal are provided in Section 7.1.4 – Other Procedures. 
A subject must be discontinued from the trial for any of the following reasons: 
5.9.[ADDRESS_734826] or legal representative (such as a parent or legal guardian) withdraws 
consent. 
5.9.6 Confirmed radiographic disease progression 
5.9.7 Intercurrent illness that prevents further administration of treatment per protocol 
5.9.8 Investigator’s decision to withdraw the subject 
5.9.[ADDRESS_734827] will be followed for 30 days for adverse event monitoring (serious adverse 
events will be collected for 90 days after the end of treatment). Subjects who discontinue for 
reasons other than progressive disease will have post-treatment follow-up for disease status until 
disease progression, initiating a non-study cancer treatment, withdrawing consent or becoming lost 
to follow-up. After documented disease progression each subject will be followed by [CONTACT_559416], withdrawal of consent, or the end of the study, whichever occurs first. 
5.[ADDRESS_734828] Replacement Strategy 
Patients who drop out before starting pembrolizumab will be replaced. In addition, patients who 
come off study before completing surgery without grade ≥3 toxicity will be replaced. The 
frequency of each of these events will be reported and reasons for replacement reviewed. 
5.10 Clinical Criteria for Early Trial Termination 
Early trial termination will be the result of the criteria specified below: 
1. Quality or quantity of data recording is inaccurate or incomplete 
2. Poor adherence to protocol and regulatory requirements 
3. Incidence or severity of adverse drug reaction in this or other studies indicates a 
potential health hazard to subjects 
4. Plans to modify or discontinue the development of the study drug 
In the event of [COMPANY_006] decision to no longer supply study drug, ample notification will be provided 
UCSF Helen Diller Family Comprehensive Cancer Center  
Version date: 03/29/2021  Protocol CC#:  166520 
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page [ADDRESS_734829] treatment can be made. 
 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 0 of 82  6.0 TRIAL FLOW CHART 
6.1 Study Flow Chart 
Trial Period:  Screeninga   Treatment Cyclesb  Surgical Treatment Follow -Up 
Treatment Cycle:  Screening  1 2 End- Induction/  
Safety Visit  SRTc  Surgical Treatment  Post-Treatment/  
Safety Visitse  
Scheduling Window:  -28d to -1d ± 3d ± 3d No later than 
7d (± 3d) No later than  7d 
(± 3d) no later than 6wksd  At 30d, 90d, 
180d,360d after 
surgery  (+14d)  
Administrative Procedures  
Informed Consent X       
Inclusion/Exclusion Criteria  X       
Demographics and Medical 
History  X       
Prior and Concomitant Medication 
Review  X X X X  X X 
Trial Treatment Administration   X X     
Post-study anticancer therapy 
status        X 
Survival Status        X 
Clinical Procedures/Assessments  
Review Adverse Events   X X X  X X 
Full Physical Examination  X       
Directed Physical Examination  X  X   X 
Vital Signs and Weight  X X  X   X 
ECOG Performance Status  X X  X   X 
Laboratory Procedures/Assessmentsf  
Pregnancy Test – Urine or Serum  β-
HCGg X       
Coagulation  X       
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 1 of 82  Trial Period:  Screeninga   Treatment Cyclesb  Surgical Treatment Follow -Up 
Treatment Cycle:  Screening  1 2 End- Induction/  
Safety Visit  SRTc  Surgical Treatment  Post-Treatment/  
Safety Visitse  
Scheduling Window:  -28d to -1d ± 3d ± 3d No later than 
7d (± 3d) No later than  7d 
(± 3d) no later than 6wksd  At 30d, 90d, 
180d,360d after 
surgery  (+14d)  
Hematology  X X X X  X X 
Comprehensive Serum Chemistry 
Panel  X X X X  X X 
Urinalysis  X      X 
Thyroid function X   X   X 
Efficacy Measurementsh  
Tumor Imaging (F -18 FDG PET/CT 
in screening with MRI/CT brain in 
stage II/III patients, and CT chest at 360d or as otherwise clinically 
indicated)  X      X 
Tumor Biopsies/Archival Tissue Collection/Correlative Studies Bloodi  
Archival or Newly Obtained 
Tissue Collection  X      X 
Correlative Studies Blood 
Collection  X  X X  X X 
aScreening procedures to be completed within 28 days of C1D1 with the exception of fresh tumor specimens and tumor imaging, please see information in footnotes,  
respectively.  
bPatients receive 2 cycles of pembrolizumab. 1 cycle is defined as 3 week intervals.  
cIf patient is scheduled to receive SRT, the day of radiation therapy will be no later than  7d (+/ - 3d) following the second cycle of pembrolizumab.  
dNo later than [ADDRESS_734830] dose of pembrolizumab.  
eAfter surgery, patients to return for clinical and laboratory assessments at 30 days (first follow -up visit to occur), 90 days, 180 days , and 360 days (+ 21 days) after date of surgery.  
fScreening labs performed within 10d of treatment initiation can be applied to Cycle [ADDRESS_734831] be reviewed by [CONTACT_79436].  
gFemales of childbearing potential: negative urine or serum pregnancy test within 3d prior to receiving trial treatment. If ur ine test is positive or non -confirmatory, a serum pregnancy test will be 
required.  
hAll patients to have a full -body F- 18 FDG PET/CT scan ≤75d prior to study treatment; patients with stage II and stage III disease should also have brain CT or M RI ≤75d prior to stud y treatment. 
Additional imaging during treatment will be under investigator discretion. During Follow -up phase, imaging studies are to be completed at the discretion of investigator or qualified designee.  
iNewly obtained specimen is preferred, however archived tissue will be acceptable due to inaccessibility or subject safety concern. Specimens that are newly obtained are defined as collection up to 120d 
prior to initiation of study treatment.  
For correlative studies and blood collection : research -donated blood will be collected pre -pembrolizumab infusion for cycle 1 and cycle 2, at the safety visit during cycle 2 (blood should be collected 
prior to SRT administration if patient will receive SRT), prior to surgical treatment, and at each post -treatment/safety follow -up visit (30d, 90d, 180d and 360d (+14d) after surgery).  
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 2 of 82  6.2 Trial Procedures 
The Trial Flow Chart - Section 6.0 summarizes the trial procedures to be performed at each visit. 
Individual trial procedures are described in detail below. It may be necessary to perform these 
procedures at unscheduled time points if deemed clinically necessary by [CONTACT_093]. 
Furthermore, additional evaluations/testing may be deemed necessary by [CONTACT_079] 
[INVESTIGATOR_1238]/or [COMPANY_006] for reasons related to subject safety. In some cases, such evaluation/testing may be 
potentially sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations may require 
that additional informed consent be obtained from the subject. In these cases, such evaluations/testing will be performed in accordance with those regulations.
 
6.2.1 Administrative Procedures  
[IP_ADDRESS] Informed Consent 
The Investigator must obtain documented consent from each potential subject prior to participating 
in a clinical trial. 
Consent must be documented by [CONTACT_423]’s dated signature [INVESTIGATOR_4388] [CONTACT_423]’s legally acceptable 
representative’s dated signature [INVESTIGATOR_2394] a consent form along with the dated signature [CONTACT_131029]. 
A copy of the signed and dated consent form should be given to the subject before participation in 
the trial. 
The initial informed consent form, any subsequent revised written informed consent form and any 
written information provided to the subject must receive the IRB/ERC’s approval/favorable 
opi[INVESTIGATOR_19349]. The subject or his/her legally acceptable representative should be 
informed in a timely manner if new information becomes available that may be relevant to the 
subject’s willingness to continue participation in the trial. The communication of this information 
will be provided and documented via a revised consent form or addendum to the original consent 
form that captures the subject’s dated signature [INVESTIGATOR_4388] [CONTACT_423]’s legally acceptable representative’s dated signature. 
Specifics about a trial and the trial population will be added to the consent form template at the 
protocol level. 
The informed consent will adhere to IRB/ERC requirements, applicable laws and regulations and 
Principal Investigator [CONTACT_225135]. 
[IP_ADDRESS]  Inclusion/Exclusion Criteria  
All inclusion and exclusion criteria will be reviewed by [CONTACT_559417]: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page [ADDRESS_734832] qualifies for the trial. 
[IP_ADDRESS]  Medical History  
A medical history will be obtained by [CONTACT_27404]. Medical history will 
include all active conditions, and any condition diagnosed within the prior [ADDRESS_734833] has enrolled in this study will be recorded separately and not listed as medical history.
 
[IP_ADDRESS]  Prior and Concomitant Medications Review  
[IP_ADDRESS].[ADDRESS_734834] has enrolled in this study 
will be recorded separately and not listed as a prior medication. 
[IP_ADDRESS].[ADDRESS_734835] during 
the trial. All medications related to reportable SAEs and ECIs should be recorded as defined in Section 7.2. 
[IP_ADDRESS] Disease Details and Treatments  
[IP_ADDRESS].1  Disease Details 
The investigator or qualified designee will obtain prior and current details regarding disease status. 
[IP_ADDRESS].2  Prior Treatment Details  
The investigator or qualified designee will review all prior cancer treatments including systemic treatments, radiation and surgeries.
 
[IP_ADDRESS].[ADDRESS_734836] will move into survival follow-up. 
[IP_ADDRESS]  Assignment of Screening Number  
At the time of screening, the patient will be assigned a screening number. 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 4 of 82  [IP_ADDRESS]  Assignment of Randomization Number  
At the time of randomization during dose expansion, the patient will be assigned a randomization 
number. 
[IP_ADDRESS]  Trial Compliance (Medication/Diet/Activity/Other)  
6.2.2 Clinical Procedures/Assess ments  
[IP_ADDRESS]  Adverse Event (AE) Monitoring  
The investigator or qualified designee will assess each subject to evaluate for potential new or worsening AEs as specified in the Trial Flow Chart and more frequently if clinically indicated. 
Adverse experiences will be graded and recorded throughout the study and during the follow- up 
period according to NCI CTCAE Version 4.0  (see Section 11.2). Toxicities will be characterized in terms regarding seriousness, causality, toxicity grading, and action taken with regard to trial 
treatment. 
Please refer to section 7.2 for detailed information regarding the assessment and recording of AEs. 
[IP_ADDRESS]  Full Physical Exam  
The investigator or qualified designee will perform a complete physical exam during the screening 
period. Clinically significant abnormal findings should be recorded as medical history. A full physical exam should be performed during screening, 
[IP_ADDRESS]  Directed Physical Exam  
For cycles that do not require a full physical exam per the Trial Flow Chart, the investigator or 
qualified designee will perform a directed physical exam as clinically indicated prior to trial 
treatment administration. 
[IP_ADDRESS]  Vital Signs  
The investigator or qualified designee will take vital signs at screening, prior to the administration 
of each dose of trial treatment and at treatment discontinuation as specified in the Trial Flow Chart 
(Section 6.0). Vital signs should include temperature, pulse, respi[INVESTIGATOR_697], weight and blood pressure. Height will be measured at screening only. 
[IP_ADDRESS]  Eastern Cooperative Oncology Group (ECOG) Performance Scale  
The investigator or qualified designee will assess ECOG status (see Section 11.1) at screening, prior to the administration of each dose of trial treatment and discontinuation of trial treatment as specified in the Trial Flow Chart. 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 5 of 82  [IP_ADDRESS]  Tumor Imaging and Assessment of Disease  
All patients will undergo a full-body F-18 FDG PET/CT scan within  75 days prior to start of 
treatment or randomization (only during dose expansion). Patients with stage II and III disease 
should have a brain CT or MRI within  75 days prior to start of treatment. 
Following the time of surgery, the investigator or qualified designee will assess disease with 
imaging studies according to the investigator’s determination of the standard of care. 
[IP_ADDRESS]  Tumor Tissue Collection and Correlative Studies Blood Sampling  
Prior to treatment or randomization (only during dose expansion), tissue collections include fresh sampling (preferred) of the primary tumor (core or excisional biopsy) or archival tissue, due to safety and inaccessibility, and blood samples (please see Table 6, Trial Flow for details). 
If the patient has clinically involved lymph nodes and investigation of the nodes is clinically 
warranted, every effort should be made to collect tissue via core needle biopsy from the involved 
lymph nodes. If bronchoscopy is performed, it is highly encouraged to collect lavage specimens 
as well, although this is not mandatory. 
Research-donated blood will be collected prior to pembrolizumab infusion during cycle 1 and 
cycle 2; prior to surgical treatment, and at each post-treatment/safety follow-up visit (30d, 90d, 180d and 360d (+14d) after surgery). 
Overall Schema: 
 
* Cycle 2 of pembrolizumab should be given except as recommended per protocol, section [IP_ADDRESS].  
** SRT is delivered within 7 days +/ - 3 days of second pembrolizumab cycle. If second cycle is not given 
due to discontinuation, SRT should not be given (patient should continue to surgery when deemed safe by 
[CONTACT_559403]).  

UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 6 of 82  ^ Surgery will take place no later than [ADDRESS_734837] dose of pembrolizumab, e.g. no later than 
week 7, or if two cycles of pembrolizumab were given, week 10.  
# Adjuvant blood collection will take place at follow -up visits (30d, 90d, 180d and 360d ( +14d) after 
surgery).  
6.2.3 Laboratory Procedures/Assessments  
Details regarding specific laboratory procedures/assessments to be performed in this trial are 
provided below. Laboratory Safety Evaluations (Hematology, Chemistry and Urinalysis) 
Laboratory tests for hematology, chemistry, urinalysis, and others are specified in Table 5. 
Table 5 Laboratory Tests 
Hematology  Chemistry  Urinalysis  Other  
Hematocrit  Albumin  Blood  Serum β -human chorionic 
gonadotropin † 
Hemoglobin  Alkaline phosphatase  Glucose  (β-hCG) † 
Platelet count  Alanine aminotransferase (ALT)  Protein  PT (INR)  
WBC (total and differential)  Aspartate aminotransferase (AST)  Specific gravity  aPTT  
Red Blood Cell Count  Lactate dehydrogenase (LDH)  Microscopic exam  
(If abnormal)  Free thyroxine (T4)  
Absolute Neutrophil Count Carbon Dioxide ‡ results are noted  Thyroid stimulating hormone 
(TSH)  
Absolute Lymphocyte Count  (CO2 or biocarbonate)  Urine pregnancy test † PK 
 Uric Acid   Blood for correlative studies  
 Calcium    
 Chloride    
 Glucose    
 Phosphorus   
 Potassium    
 Sodium    
 Magnesium   
 Total Bilirubin    
 Direct Bilirubin (If total bilirubin 
is elevated above the upper limit 
of normal)    
 Total protein    
 Blood Urea Nitrogen    
 Creatinine    
† Perform on women of childbearing potential only. If urine pregnancy results cannot be confirmed as negative, a serum 
pregnancy test will be required.  
‡ If considered standard of care in your region.  
After Cycle 1, pre-dose laboratory procedures can be conducted up to [ADDRESS_734838] be reviewed by [CONTACT_559418]. 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page [ADDRESS_734839] 4 (four) 10mL green top tubes of blood specimens collected prior to 
pembrolizumab infusion during cycle [ADDRESS_734840]-
treatment/safety follow-up visit (30d, 90d, 180d and 360d (+14d) after surgery). 
Sample collection, storage and shipment instructions for blood samples are provided in the 
Laboratory Manual. 
6.2.5 Other Procedures  
Fresh sampling (preferred) of the primary tumor (core or excisional biopsy) is required, or archival 
tissue may be substituted for reasons due to safety and inaccessibility. 
If the patient has clinically involved lymph nodes and investigation of the nodes is clinically 
warranted, every effort should be made to collect tissue via core needle biopsy from the involved 
lymph nodes. 
[IP_ADDRESS]   Pretreatment samples  
Core biopsies of primary tumor +/- involved lymph nodes will be performed by a qualified 
radiologist, pathologist, surgeon, or pulmonologist. One to four core biopsies will be performed 
(number determined by [CONTACT_559419]). Core biopsies are required, however if it is deemed technically infeasible, 
or if a core biopsy is deemed very high risk by [CONTACT_24476], then fine-
needle aspi[INVESTIGATOR_1516] (FNA) may be acceptable in 1-[ADDRESS_734841] cases based on pre-approval 
by [CONTACT_355901]. 
For intraparenchymal lung biopsies, an 18G core needle biopsy is preferred. If this is not 
considered to be safe by [CONTACT_559420], then an FNA with a higher gauge 
needle will be acceptable. 
Biopsy sites other than intraparenchymal lung should use a 16 G if possible, but 18 G or FNA will 
be acceptable if the physician performing the biopsy feels that it is safer. One to three needle passes 
at minimum will be obtained, but if the physician determines it is safe, up to 6 passes may be 
obtained. 
Sample collection, storage and shipment instructions for pre-treatment tissue samples are provided 
in the Laboratory Manual. 
[IP_ADDRESS]  Post -treatment samples:  
Patients will undergo surgical resection of their primary tumor and associated lymph nodes. 
Patients in cohort [ADDRESS_734842] received pembrolizumab and radiation to half of the primary tumor. 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page [ADDRESS_734843] taken from the primary tumor tissue 
that was treated with pembrolizumab only (medially oriented half of tumor). The portion of tumor which received radiation is the lateral aspect of the tumor relative to the patient. 
Therefore, mandated post-treatment tissue samples should always be removed from the medial 
aspect of the tumor. 
If it is feasible and specimen collection will not interfere with the patient’s clinical care, tissue 
samples should also be collected from the radiated portion of the tumor (lateral aspect). These 
tumor samples should be labeled so that their orientation (medial vs lateral) is clear. 
Samples from clinically involved lymph nodes are requested if feasible and if collection will not 
interfere with the patient’s clinical care. These samples should be labeled by [CONTACT_559421]. 
Sample collection, storage and shipment instructions for post-treatment tissue samples are 
provided in the Laboratory Manual. 
[IP_ADDRESS]  Lavage (fluid) specimens  
If bronchoscopy is performed, it is highly encouraged to collect lavage specimens as well, although 
this is not mandatory. If a patient has clinical indication for bronchoscopy, lavage fluid may be 
obtained. Any excess leftover fluid, up to 1000mL, should be submitted. 
Sample collection, storage and shipment instructions for fluid samples are provided in the 
Laboratory Manual. 
6.2.6 Withdrawal/Discontinuation  
When a subject discontinues/withdraws prior to trial completion, all applicable activities scheduled 
for the final trial visit should be performed at the time of discontinuation. Any adverse events 
which are present at the time of discontinuation/withdrawal should be followed in accordance with 
the safety requirements outlined in Section 7.2 - Assessing and Recording Adverse Events. 
6.2.7 Blinding/Unblinding  
This trial is open label; therefore, the subject, the trial site personnel, the Principal Investigator 
[INVESTIGATOR_1238]/or designee are not blinded to treatment. 
6.2.8 Visit Requirements  
Visit requirements are outlined in Section 6.0 - Trial Flow Chart. Specific procedure-related details 
are provided above in Section 7.1 - Trial Procedures. 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page [ADDRESS_734844] dose of pembrolizumab. A second dose of pembrolizumab 
will be delivered 3 weeks later, +/- 3 days. 
If the patient is scheduled to receive SRT on the protocol, the day of radiation delivery will be no 
later than 7 days following the date anticipated for administration of the second cycle of pembrolizumab, +/- 3 days. If the second cycle is not given, then SRT should not be given. 
Surgical resection, if the patient is medically and physically able to undergo the procedure, should 
be delivered no later than 6 weeks (42 days +/- 3 days) after the last dose of pembrolizumab. 
6.2.[ADDRESS_734845]-Treatment/Safety Follow-Up Visits
 
After the date of surgery, patients will return for clinical and laboratory assessments at 30 days 
(first follow-up visit), 90 days, 180 days, and 360 days (+/- 14 days) after the date of surgery. 
These assessments are required but imaging studies are to be ordered at the discretion of the investigator or a qualified designee. 
All AEs that occur prior to the Safety Follow-Up Visit should be recorded. Subjects with an AE 
of Grade > [ADDRESS_734846]-study anti-neoplastic treatment will be collected if new treatment is initiated. 
Correlative blood samples will be collected at each follow-up visit. Details are provided in 
Section 6.0 – Trial Flow Chart 
6.3 Assessing and Recording Adverse Events 
6.3.1 Definitions of Adverse Events  
[IP_ADDRESS]  Adverse Event  
An adverse event (also known as an adverse experience) is defined as any untoward medical 
occurrence associated with the use of a drug in humans, whether or not considered drug related. 
More specifically, an adverse event (can be any unfavorable and unintended sign (e.g., an abnormal 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 10 of 82  laboratory finding), symptom, or disease temporally associated with the use of a drug, without any 
judgment about causality. An adverse event can arise from any use of the drug (e.g., off-label use, 
use in combination with another drug) and from any route of administration, formulation, or dose, 
including an overdose. 
[IP_ADDRESS]  Adverse reaction  
An adverse reaction is defined as any adverse event caused by [CONTACT_2224] a drug. Adverse reactions 
are a subset of all suspected adverse reactions for which there is reason to conclude that the drug caused the event. 
[IP_ADDRESS]  Suspected  
A suspected adverse reaction is defined as any adverse event for which there is a reasonable possibility that the drug caused the adverse event. For the purposes of IND safety reporting, 
“reasonable possibility” indicates that there is evidence to suggest a causal relationship between 
the drug and the adverse event. A suspected adverse reaction implies a lesser degree of certainty about causality than an adverse reaction. 
[IP_ADDRESS]  Unexpected  
An adverse event or suspected adverse reaction is considered unexpected if it is not listed in the 
investigator brochure or package insert(s), or is not listed at the specificity or severity that has been 
observed, or, if an investigator brochure is not required or available, is not consistent with the risk 
information described in the general investigational plan or elsewhere in the current application. 
“Unexpected,” as used in this definition, also refers to adverse events or suspected adverse 
reactions that are mentioned in the investigator brochure as occurring with a class of drugs or as 
anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation. 
Adverse events that would be anticipated to occur as part of the disease process are considered 
unexpected for the purposes of reporting because they would not be listed in the investigator 
brochure. For example, a certain number of non-acute deaths in a cancer trial would be anticipated as an outcome of the underlying disease, but such deaths would generally not be listed as a 
suspected adverse reaction in the investigator brochure. 
Some adverse events are listed in the Investigator Brochure as occurring with the same class of 
drugs, or as anticipated from the pharmacological properties of the drug, even though they have 
not been observed with the drug under investigation. Such events would be considered unexpected 
until they have been observed with the drug under investigation. For example, although angioedema is anticipated to occur in some patients exposed to drugs in the ACE inhibitor class 
and angioedema would be described in the investigator brochure as a class effect, the first case of 
angioedema observed with the drug under investigation should be considered unexpected for 
reporting purposes.
 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 11 of 82  [IP_ADDRESS]  Serious  
An adverse event or suspected adverse reaction is considered serious if, in the view of either the 
investigator or Principal Investigator, it results in any of the following outcomes: 
[IP_ADDRESS].1 Death  
[IP_ADDRESS].2 Life-threatening adverse event 
[IP_ADDRESS].3 Inpatient hospi[INVESTIGATOR_1081] 
[IP_ADDRESS].[ADDRESS_734847] normal life function 
[IP_ADDRESS].5 Congenital anomaly/birth defect 
Important medical events that may not result in death, are life-threatening, or require 
hospi[INVESTIGATOR_708], based upon appropriate medical judgment, they 
may jeopardize the patient or subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse. 
[IP_ADDRESS]  Life-threatening  
An adverse event or suspected adverse reaction is considered life-threatening if, in the view of 
either the investigator or Principal Investigator, its occurrence places the patient or subject at 
immediate risk of death. It does not include an adverse event or suspected adverse reaction that, 
had it occurred in a more severe form, might have caused death. 
6.3.2 Recording of an Adverse Event  
All Grade 3 and above adverse events will be entered into OnCore ®, whether or not the event is 
believed to be associated with use of the study drug. Data about these events and their severity will 
be recorded using the NCI CTCAE v4.0. 
If there are specific data plans to this study, such as Grade 1 & 2 AEs are also being entered into 
OnCore, describe that process here. 
The Investigator will assign attribution of the possible association of the event with use of the 
investigational drug, and this information will be entered into OnCore ® using the classification 
system listed below: 
Attribution categories are: 
• Definite – The adverse event is clearly related to the investigational agent(s) or study 
procedure. 
• Probable – The adverse event is likely related to the investigational agent(s) or study 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 12 of 82  procedure. 
• Possible – The adverse event may be related to the investigational agent(s) or study 
procedure. 
• Unrelated – the adverse event is clearly not related to the investigational agent(s) or 
study procedure. 
Signs or symptoms reported as adverse events will be graded and recorded by [CONTACT_40607]. When specific adverse events are not listed in the CTCAE they will be 
graded by [CONTACT_40608], mild , moderate or severe according to the following grades 
and definitions:  
Grade 0 No AE (or within normal limits) 
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated 
Grade 2 Moderate; minimal, local, or noninvasive intervention (e.g., packing, 
cautery) indicated; limiting age-appropriate instrumental activities of daily living (ADL) 
Grade 3: Severe or medically significant but not immediately life-threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self-care ADL 
Grade 4: Life-threatening consequences; urgent intervention indicated  
Grade 5: Death related to AE 
6.3.[ADDRESS_734848] with the investigational drug may be conducted if considered both safe and ethical by [CONTACT_737]. 
6.3.4 Adverse Events Monitoring
 
All adverse events, whether or not unexpected, and whether or not considered to be associated 
with the use of the study drug, will be entered into OnCore ®, as noted above. 
The Investigator will assess all adverse events and determine reportability requirements to the 
UCSF Data and Safety Monitoring Committee (DSMC) and UCSF’s Institutional Review Board, 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page [ADDRESS_734849] (IRB); and, when the study is conducted under an Investigational 
New Drug Application (IND), to the Food and Drug Administration (FDA) if it meets the FDA reporting criteria. 
[The manufacturer and/or grant sponsor may also need to be notified, as applicable.] 
All adverse events entered into OnCore
® will be reviewed by [CONTACT_559422] a weekly basis. The Site Committee will review 
and discuss at each weekly meeting the selected toxicity, the toxicity grade, and the attribution of 
relationship of the adverse event to the administration of the study drug(s). 
All grade(s) 3-5 adverse events entered into OnCore® will be reviewed on a monthly basis at the 
Site Committee meetings. The Site Committee will review and discuss the selected toxicity, the 
toxicity grade, and the attribution of relationship of the adverse event to the administration of the 
study drug(s).  
In addition, all suspected adverse reactions considered “serious” entered into OnCore®, will be 
reviewed and monitored by [CONTACT_394267], which take place every six weeks. 
For a detailed description of the Data and Safety Monitoring Plan for a Multicenter Phase 2 or 3 
Institutional Study at the Helen Diller Comprehensive Cancer Center please refer Appendix 4 
Multicenter Institutional Studies.  
6.4.5 Expedited Reporting  
[IP_ADDRESS]  Reporting to the Data and Safety Monitoring Committee  
If a death occurs during the treatment phase of the study or within [ADDRESS_734850] 
administration of the study drug(s) and it is determined to be related either to the study drug(s) or 
to a study procedure, the Investigator or his/her designee must notify the DSMC Chair (or qualified 
alternate) within [ADDRESS_734851] may be by [CONTACT_14223] e-mail. 
[IP_ADDRESS]  Reporting to UCSF Institutional Review Board (IRB)  
The Principal Investigator [INVESTIGATOR_559390] “Unanticipated 
Problem” (UP) within 10 business days of his/her awareness of the event. 
[IP_ADDRESS]  Expedited Reporting to the Food and Drug Administration  
If the study is being conducted under an IND, the Sponsor-Investigator is responsible for 
determining whether or not the suspected adverse reaction meets the criteria for expedited 
reporting in accordance with Federal Regulations (21 CFR §312.32). 
The Investigator must report in an IND safety report any suspected adverse reaction that is both 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 14 of 82  serious and unexpected. The Sponsor-Investigator needs to ensure that the event meets all three 
definitions: 
[IP_ADDRESS].1 Suspected adverse reaction - A suspected adverse reaction is defined as any 
adverse  event for which there is a reasonable possibility that the treatment or 
procedure caused the adverse event. For the purposes of IND safety reporting, 
“reasonable possibility” indicates that there is evidence to suggest a causal 
relationship between  the treatment or procedure and the adverse event. A 
suspected adverse reaction  implies a lesser degree of certainty about causality 
than an adverse reaction. 
[IP_ADDRESS].2 Unexpected - An adverse event or suspected adverse reaction is considered unexpected if it is not listed in the investigator brochure or package insert(s), or is 
not  listed at the specificity or severity that has been observed, or, if an 
investigator brochure is not required or available, is not consistent with the risk 
information described in the general investigational plan or elsewhere in the 
current application. 
“Unexpected,” as used in this definition, also refers to adverse events or suspected 
adverse reactions that are mentioned in the investigator brochure as occurring 
with a class of treatment or procedure or as anticipated from the pharmacological 
properties of the treatment or procedure, but are not specifically mentioned as 
occurring with the particular treatment or procedure under investigation. 
Adverse events that would be anticipated to occur as part of the disease process 
are considered unexpected for the purposes of reporting because they would not 
be listed in the investigator brochure. For example, a certain number of non-acute 
deaths in a cancer trial would be anticipated as an outcome of the underlying 
disease, but such deaths would generally not be listed as a suspected adverse 
reaction in the investigator brochure. 
Some adverse events are listed in the Investigator’s Brochure as occurring with 
the same class of treatment, or as anticipated from the pharmacological properties 
of the drug, even though they have not been observed with the drug under investigation. 
Such events would be considered unexpected until they have been observed with 
the drug under investigation. For example, although angioedema is anticipated to 
occur in some patients exposed to drugs in the ACE inhibitor class and angioedema would be described in the investigator brochure as a class effect, the 
first case of angioedema observed with the drug under investigation should be considered unexpected for reporting purposes. 
[IP_ADDRESS].3 Serious - An adverse event or suspected adverse reaction is considered serious if, 
in  the view of either the investigator or Principal Investigator, it results in any of 
the following outcomes: 
[IP_ADDRESS].3.1 Death  
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 15 of 82  [IP_ADDRESS].3.2 Life-threatening adverse event 
[IP_ADDRESS].3.3 Inpatient hospi[INVESTIGATOR_1081] 
[IP_ADDRESS].3.[ADDRESS_734852] normal life function 
[IP_ADDRESS].3.5 Congenital anomaly/birth defect 
Important medical events that may not result in death, are life-threatening, or require hospi[INVESTIGATOR_708], based upon appropriate 
medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of 
drug dependency or drug abuse. 
If the adverse event does not meet all three of the definitions, it should not be 
submitted as an expedited IND safety report. 
The timeline for submitting an IND safety report to FDA is no later than 15 
calendar days after the Investigator determines that the suspected adverse reaction 
qualifies for reporting (21 CFR 312.32(c)(1)). Any unexpected fatal or life-threatening suspected adverse reaction will be reported 
to FDA no later than 7 calendar days after the Investigator’s initial receipt of the 
information (21 CFR 312.32(c)(2)). 
Any relevant additional information that pertains to a previously submitted IND 
safety report will be submitted to FDA as a Follow-up IND Safety Report without 
delay, as soon as the information is available (21 CFR 312.32(d)(2)). 
[IP_ADDRESS]  Expedited Reporting to [COMPANY_006].  
Investigators must report all SAEs to [COMPANY_006] within 24 hours of becoming aware of the event. 
6.4.6 Definition of an Overdose for This Protocol and Reporting of Overdose to the Principal 
Investigator [INVESTIGATOR_559391], an overdose of pembrolizumab will be defined as any dose of 1,000 mg 
or greater (≥5 times the indicated dose). No specific information is available on the treatment of 
overdose of pembrolizumab. Appropriate supportive treatment should be provided if clinically 
indicated. In the event of overdose, the subject should be observed closely for signs of toxicity. 
Appropriate supportive treatment should be provided if clinically indicated. 
If an adverse event(s) is associated with (“results from”) the overdose of a [COMPANY_006] product, the 
adverse event(s) is reported as a serious adverse event, even if no other seriousness criteria are 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 16 of 82  met. 
If a dose of [COMPANY_006]’s product meeting the protocol definition of overdose is taken without any 
associated clinical symptoms or abnormal laboratory results, the overdose is reported as a non- 
serious Event of Clinical Interest (ECI), using the terminology “accidental or intentional overdose 
without adverse effect.” 
All reports of overdose with and without an adverse event must be reported within 24 hours to the 
Principal Investigator [INVESTIGATOR_295760] 2 working days hours to [COMPANY_006] Global Safety. (Attn: Worldwide 
Product Safety; FAX ) 
6.4.[ADDRESS_734853] (spontaneously 
reported to them) that occurs during the trial. 
Pregnancies and lactations that occur after the consent form is signed but before treatment 
allocation/randomization must be reported by [CONTACT_105943], or are the result of a protocol-specified intervention, including but not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a procedure. 
Pregnancies and lactations that occur from the time of treatment allocation/randomization through 
[ADDRESS_734854] be followed to the completion/termination of the pregnancy. Pregnancy 
outcomes of spontaneous abortion, missed abortion, benign hydatidiform mole, blighted ovum, 
fetal death, intrauterine death, miscarriage and stillbirth must be reported as serious events 
(Important Medical Events). If the pregnancy continues to term, the outcome (health of infant) must also be reported. 
Such events must be reported within 24 hours to the Principal Investigator [INVESTIGATOR_295760] 2 working 
days to [COMPANY_006] Global Safety. (Attn: Worldwide Product Safety; FAX ) 
6.4.8 Immediate Reporting of Adverse Events to the Principal Investigator [INVESTIGATOR_559380]
 
[IP_ADDRESS]  Serious Adverse Events 
A serious adverse event is any adverse event occurring at any dose or during any use of [COMPANY_006]’s product that: 
[IP_ADDRESS].1 Results in death; 
[IP_ADDRESS].2 Is life threatening; 
[IP_ADDRESS].3 Results in persistent or significant disability/incapacity; 
[IP_ADDRESS].4 Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059]; 

UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 17 of 82  [IP_ADDRESS].5 Is a congenital anomaly/birth defect; 
[IP_ADDRESS].6 Is another important medical event 
[IP_ADDRESS].7 Note: In addition to the above criteria, adverse events meeting either of the below 
criteria, although not serious per ICH definition, are reportable to the [COMPANY_006] in the 
same timeframe as SAEs to meet certain local requirements. Therefore, these  
events are considered serious by [CONTACT_131892]. 
[IP_ADDRESS].7.1 is a new cancer (that is not a condition of the study); 
[IP_ADDRESS].7.2 is associated with an overdose. 
Refer to Table 6 for additional details regarding each of the above criteria. 
For the time period beginning when the consent form is signed until treatment 
allocation/randomization, any serious adverse event, or follow up to a serious adverse event, 
including death due to any cause other than progression of the cancer under study that occurs to 
any subject must be reported within [ADDRESS_734855] to be excluded from the trial, or is the result 
of a protocol-specified intervention, including but not limited to washout or discontinuation of 
usual therapy, diet, placebo treatment or a procedure. 
For the time period beginning at treatment allocation/randomization through [ADDRESS_734856] be followed up for outcome. 
SAE reports and any other relevant safety information are to be forwarded to the [COMPANY_006] 
Global Safety facsimile number:  
A copy of all 15 Day Reports and Annual Progress Reports is submitted as required by [CONTACT_8415], 
European Union (EU), Pharmaceutical and Medical Devices agency (PMDA) or other local 
regulators. Investigators will cross reference this submission according to local regulations to the 
[COMPANY_006] Investigational Compound Number (IND, CSA, etc.) at the time of submission. 
Additionally, investigators will submit a copy of these reports to [COMPANY_006] & Co., Inc. (Attn: Worldwide Product Safety; FAX ) at the time of submission to FDA. 

UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 18 of 82  [IP_ADDRESS]  Events of Clinical Interest  
Selected non-serious and serious adverse events are also known as Events of Clinical Interest (ECI) 
and must be reported within 24 hours to the Principal Investigator [INVESTIGATOR_295760] 2 working days to 
[COMPANY_006] Global Safety. (Attn: Worldwide Product Safety; FAX ). 
For the time period beginning when the consent form is signed until treatment 
allocation/randomization, any ECI, or follow up to an ECI, that occurs to any subject must be 
reported within [ADDRESS_734857] to be excluded from the trial, or is the result of a protocol- specified 
intervention, including but not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a procedure. 
For the time period beginning at treatment allocation/randomization through [ADDRESS_734858] for this trial include: 
1. an overdose of [COMPANY_006] product, as defined in Section 7.2.[ADDRESS_734859] of protocol-specified laboratory testing or unscheduled laboratory testing. * 
*Note: These criteria are based upon available regulatory guidance documents. The purpose of the 
criteria is to specify a threshold of abnormal hepatic tests that may require an additional evaluation 
for an underlying etiology. 
[IP_ADDRESS]  Protocol -Specific Exceptions to Serious Adverse Event Reporting  
Efficacy endpoints as outlined in this section will not be reported to [COMPANY_006], unless there is evidence 
suggesting a causal relationship between the drug and the event. Any such event will be submitted 
to the Principal Investigator [INVESTIGATOR_874] 24 hours and to [COMPANY_006] Global Safety within 2 working days either by [CONTACT_131008]. 
Specifically, the suspected/actual events covered in this exception include any event that is disease 
progression of the cancer under study. 
The Principal Investigator [INVESTIGATOR_559392]. Any suspected endpoint which upon review is 

UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 19 of 82  not progression of the cancer under study will be forwarded to [COMPANY_006] Global Safety as a SAE 
within 2 working days of determination that the event is not progression of the cancer under study 
Hospi[INVESTIGATOR_77989] (e.g., transportation issues etc.) will not be considered a 
SAE.  
[IP_ADDRESS] Evaluating Adverse Events  
An investigator who is a qualified physician will evaluate all adverse events according to the NCI 
Common Terminology for Adverse Events (CTCAE), version 4.0. Any adverse event which changes CTCAE grade over the course of a given epi[INVESTIGATOR_528073]/worksheets. 
All adverse events regardless of CTCAE grade must also be evaluated for seriousness. 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 20 of 82  Table 6 Evaluating Adverse Events 
An investigator, who is a qualified physician, will evaluate all adverse events as to:  
V4.0 CTCAE  
Grading  Grade 1  Mild; asymptomatic or mid symptoms; clinical or diagnostic observations only; intervention not indicated.  
 Grade 2  Moderate; minimal, local or noninvasive intervention indicated; limiting age -appropriate instrumental ADL.  
 Grade 3  Severe or medically significant but not immediately life-threatening; hospi[INVESTIGATOR_77991]; 
disabling; limiting self -care ADL.  
 Grade 4  Life threatening consequences; urgent intervention indicated.  
 Grade [ADDRESS_734860] that:  
†Results in death ; or 
†Is life threatening; or places the subject, in the view of the investigator, at immediate risk of death from the event as it occurred (Note: This does not include an 
adverse event that, had it occurred in a more severe form, might have caused death.); or  
†Results in a persistent or significant disability/incapacity (substantial disruption of one’s ability to conduct normal life functions); or  
†Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059] (hospi[INVESTIGATOR_19357], regardless of length of stay, even if the 
hospi[INVESTIGATOR_2138] a precautionary measure for continued observation . (Note: Hospi[INVESTIGATOR_19358] a pre -existing condition that has not 
worsened is not a serious adverse event. A pre -existing condition is a clinical condition that is diagnosed prior to the use of a [COMPANY_006] product and is documen ted in the 
patient’s medical history.); or  
†Is a congenital anomaly/birth defect (in offspring of subject taking the product regardless of time to diagnosis);or  
Is a new cancer (that is not a condition of the study) ( although not serious per ICH definition, is reportable to the Principal Investigator [INVESTIGATOR_874] 24 hours and to 
[COMPANY_006] within 2 working days to meet certain local requirements); or 
Is an overdose (whether accidental or intentional). Any adverse event associated with an overdose is considered a serious adverse event for collectio n purposes. An 
overdose that is not associated with an adverse event is considered a non -serious event of clinical interest and mus t be reported within [ADDRESS_734861] and may require medical or surgical interventio n to prevent one of the outcomes listed  
  previously (designated above by a †).  
Duration  Record the start and stop dates of the adverse event. If less than [ADDRESS_734862] to be discontinued?  
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page [ADDRESS_734863] cause the adverse event? The determination of the likelihood that [COMPANY_006] product caused the adverse event will be provided by [CONTACT_78031] a qualified physician. The investigator’s signed/dated initials on the source document or worksheet that supports the causality noted on the AE form, ensures 
that a medically qualified assessment of causality was done. This initialed document must be retained for the required regulatory time frame. The criteria below are 
intended  as reference guidelines to assist the investigator in assessi ng the likelihood of a relationship between the test drug and the adverse event based upon the 
available information.  
The following components are to be used to assess the relationship between [COMPANY_006] product and the AE ; the greater the correlation with the components 
and their respective elements (in number and/or intensity), the more likely [COMPANY_006] product caused the adverse event (AE):  
Exposure  Is there evidence that the subject was actually exposed to [COMPANY_006] product such as: reliable hi story, acceptable compliance assessment (pi[INVESTIGATOR_692],  
diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?  
Time Course  Did the AE follow  in a reasonable  temporal  sequence  from  administration  of [COMPANY_006]  product?  
Is the time of onset of the AE compatible with a drug -induced effect (applies to trials with investigational medicinal product)?  
Likely Cause  Is the AE not reasonably explained by [CONTACT_26369], other drug(s)/vaccin e(s), or other host or environmental factors  
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page [ADDRESS_734864] drug and the AE: (continued)  
to [COMPANY_006] 
Product  
(continued)  Dechallenge  Was [COMPANY_006] product discontinued or dose/exposure/frequency reduced?  
 
If yes, did the AE resolve or improve?  
 
If yes, this is a positive dechallenge. If no, this is a negative dechallenge.  
 
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent disability; (2) the AE resolved/improve d despi[INVESTIGATOR_559393]; or (3) the trial is a single-d ose drug trial); or (4) product(s) is/are only used one time.)  
Rechallenge  Was the subject re -exposed to [COMPANY_006] product in this study?  
 
If yes, did the AE recur or worsen?  
 
If yes, this is a positive rechallenge. If no, this is a negative rechallenge. 
 
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent disability, or (2) the trial is  a single- dose drug trial); or (3) 
product(s) is/are used only one time).  
 
NOTE: IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE BEEN CAUSED 
BY [CONTACT_131889], OR IF REEXPOSURE TO MERCK PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT RISK TO THE 
SUBJECT, THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY [CONTACT_470928] [INVESTIGATOR_559394]. 
 Consistency  Is the clinical/pathological presentation of the AE consistent with previo us knowledge regarding [COMPANY_006] product or drug class pharmacology or  with 
Trial  toxicology?  
Treatmen
t Profile  
The assessment of relationship will be reported on the case report forms /worksheets by [CONTACT_19427] a qualified physic ian according to his/her best clinical judgment, 
including consideration of the above elements.  
Record one of the following  Use th e following scale of criteria as guidance (not all criteria must 
be present to be indicative of [COMPANY_006] product relationship).  
Yes, there is a reasonable There is evidence of exposure to [COMPANY_006] product. The temporal sequence 
of possibility of [COMPANY_006] product  The AE is more likely explained by [CONTACT_131891]. 
relationship.  the AE onset relative to the administration of [COMPANY_006] product is 
reasonable.  
No, there is not a reasonable  Subject did not receive the [COMPANY_006] product OR temporal sequence of the 
possibility of [COMPANY_006] product  the AE is more likely explained by [CONTACT_559423]. relationship AE onset relative to administration of [COMPANY_006] product is not reasonable 
OR 
(Also entered for a subject with overdose without an associated AE.) 
 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 23 of 82  6.4.9 Principal Investigator [INVESTIGATOR_559395], IRB/IECs and investigators in 
accordance with all applicable global laws and regulations. 
7.0 STATISTICAL ANALYSIS PLAN 
7.1 Statistical Analysis Plan Summary 
Forty evaluable subjects will be enrolled in the study. Two sequential run-in cohorts will be 
conducted to confirm safety, after which the remaining patients will be randomized between 
preoperative pembrolizumab versus preoperative pembrolizumab and SRT. The primary study 
endpoint is based on the anticipated degree of improvement in tumor immunogenicity as measured 
by [CONTACT_559424]3+ T cells/ μm 2 in the lung cancer tissue. 
7.2 Statistical Analysis Plan 
Sample size justification: 
The sample size is based upon the anticipated number of patients who will have samples that will 
be useful for study of immunologic changes in the number of infiltrating CD3+ T cells/μm 2 in the 
lung cancer tissue between the pre-treatment (baseline) biopsy and post-treatment thoracotomy specimens. 
The sample size is fixed at [ADDRESS_734865] of patients 
may not be able to complete a new successful core needle biopsy procedure and only prior archived 
tissues will be available for any analysis (which may eventually turn out to be insufficient to 
evaluate for primary endpoint). These patients who enrolled but whose core biopsy is later found 
to be inadequate after initiation of therapy will be allowed to continue on the protocol but will not be included in the primary endpoint. 
The null hypothesis is that a two-fold increase will be seen in 15% of the evaluable 26 patients 
(assuming up to one third of samples may be inevaluable for primary endpoint). The alternative 
hypothesis is that a two-fold increase will be seen in 40% of the evaluable 26 patients. This yields 
90% statistical power, with one sided 5% alpha level based on an exact binomial test. 
The goal of achieving a two-fold increase in 40% of the evaluable population is a reasonable one, 
as estimated from a previous study showing greater-than-three-fold increase in 57% of patients 
when CD3+ T cells/um
2 were measured in prostate cancer tissue treated with a cell- based cancer 
immunotherapy, with a null hypothesis having been set at a two-fold increase in 15% of the population (Fong 2014). The current study includes immunotherapy +/- stereotactic radiation 
therapy, both of which are anticipated to create increased immunogenicity against NSCLC. 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 24 of 82  It is anticipated that accrual will be completed in 10 months (4 patients per month), with each 
patient treated for approximately 2.5-[ADDRESS_734866] under the null hypothesis of 15%. Exact 95% 
confidence intervals will be presented with associated estimate. P <0.[ADDRESS_734867] Name & Potency  Dosage Form  
Pembrolizumab 50 mg  Lyophilized Powder for Injection  
Pembrolizumab 100 mg/ 4mL Solution for Injection 
8.2 Packaging and Labeling Information 
Clinical  supplies  will  be  affixed  with  a  clinical  label  in  accordance  with  
regulatory requirements. 
8.3 Clinical Supplies Disclosure 
This trial is open-label; therefore, the subject, the trial site personnel, the Principal 
Investigator [INVESTIGATOR_1238]/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text; random code/disclosure envelopes or lists are not provided. 
8.[ADDRESS_734868] be recorded by [CONTACT_559425]: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 25 of 82  the trial site. 
Clinical supplies may not be used for any purpose other than that stated in the protocol. 8.5 Returns and Reconciliation 
The investigator is responsible for keepi[INVESTIGATOR_270200], the amount dispensed to and returned by [CONTACT_270227]. 
Upon completion or termination of the study, all unused and/or partially used 
investigational product will be destroyed at the site per institutional policy. It is the 
Investigator’s responsibility to arrange for disposal of all empty containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, 
local and institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
9.[ADDRESS_734869] their origin 
in the Declaration of Helsinki as stated in 21 CFR §312.120(c)(4); consistent with GCP 
and all applicable regulatory requirements. 
Before initiating this trial, the Investigator will have written and dated approval from the 
Institutional Review Board for the protocol, written informed consent form, subject 
recruitment materials, and any other written information to be provided to subjects before any protocol related procedures are performed on any subjects. 
The clinical investigation will not begin until either FDA has determined that the study 
under the Investigational Drug Application (IND) is allowed to proceed or the Investigator 
has received a letter from FDA stating that the study is exempt from IND requirements. 
The Investigator must comply with the applicable regulations in Title 21 of the Code of 
Federal Regulations (21 CFR §50, §54, and §312), GCP/ICH guidelines, and all applicable 
regulatory requirements. The IRB must comply with the regulations in 21 CFR §[ADDRESS_734870] Approval 
The protocol, the proposed informed consent form, and all forms of participant information 
related to the study (e.g. advertisements used to recruit participants) will be reviewed and 
approved by [CONTACT_317014] (IRB). Prior to obtaining IRB approval, 
the protocol must be approved by [CONTACT_559426] (PRC). The initial protocol and all 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page [ADDRESS_734871] then notify the IRB in writing within five (5) working days after 
implementation. The Study Chair and the UCSF study team will be responsible for updating any participating sites. 
9.5 Handling and Documentation of Clinical Supplies 
The UCSF Principal Investigator [INVESTIGATOR_80040], dispensation, return, or other disposition of all investigational drugs. 
The date, quantity and batch or code number of the drug, and the identification of patients 
to whom study drug has been dispensed by [CONTACT_14227]. 
The sponsor- investigator will maintain written records of any disposition of the study drug. 
The Principal Investigator [INVESTIGATOR_559396]. Furthermore, the Principal Investigator 
[INVESTIGATOR_559397]. 
9.6 Case Report Forms (CRFs) 
The Principal Investigator [INVESTIGATOR_1238]/or his/her designee will prepare and maintain adequate and 
accurate participant case histories with observations and data pertinent to the study. Study 
specific Case Report Forms (CRFs) will document safety and treatment outcomes for 
safety monitoring and data analysis. All study data will be entered into OnCore ®  via 
standardized CRFs in accordance with the CTMS study calendar, using single data entry with a secure access account. The Clinical Research Coordinator (CRC) will complete the 
CRFs as soon as possible upon completion of the study visit; the Investigator will review 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 27 of 82  and approve the completed CRFs. 
The information collected on CRFs shall be identical to that appearing in original source 
documents. Source documents will be found in the patient’s medical records maintained 
by [CONTACT_14228]. All source documentation should be kept in separate research folders 
for each patient. 
In accordance with federal regulations, the Investigator is responsible for the accuracy and 
authenticity of all clinical and laboratory data entered onto CRFs. The PI [INVESTIGATOR_14159]. 
All source documentation and CTMS data will be available for review/monitoring by [CONTACT_174803]. 
The Principal Investigator [INVESTIGATOR_174722]. At study completion, when the CRFs have been declared to be complete and accurate, 
the database will be locked. Any changes to the data entered into the CRFs after that time 
can only be made by [CONTACT_14230], the Trial Statistician, 
and the Protocol Project Manager. 
9.7 Oversight and Monitoring Plan 
The UCSF Helen Diller Family Comprehensive Cancer Center DSMC will be the 
monitoring entity for this study. The UCSF DSMC will monitor the study in accordance 
with the NCI- approved Data and Safety Monitoring Plan (DSMP). The DSMC will 
routinely review all adverse events and suspected adverse reactions considered “serious”. 
The DSMC will audit study-related activities to ensure that the study is conducted in 
accordance with the protocol, local standard operating procedures, FDA regulations, and 
Good Clinical Practice (GCP). Significant results of the DSMC audit will be 
communicated to the IRB and the appropriate regulatory authorities at the time of 
continuing review, or in an expedited fashion, as applicable. See Appendix 12.[ADDRESS_734872] (IRB). Prior to implementing this 
protocol at the participating sites, approval for the UCSF IRB approved protocol must be 
obtained from the participating site’s IRB. 
The following documents must be provided to UCSF HDFCCC before the participating 
site can be initiated and begin enrolling participants: 
• Participating Site IRB approval(s) for the protocol, appendices, informed consent 
form and HIPAA authorization 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 28 of 82  • Participating Site IRB approved consent form 
• Participating Site IRB membership list 
• Participating Site IRB’s Federal Wide Assurance number and OHRP Registration 
number 
• Curriculum vitae and medical license for each investigator and consenting 
professional 
• Documentation of Human Subject Research Certification training for investigators and key staff members at the Participating Site 
• Participating site laboratory certifications and normals 
Upon receipt of the required documents, UCSF HDFCCC will formally contact [CONTACT_14232].
 
9.[ADDRESS_734873]’s rights 
and welfare are protected and that the potential benefits and/or the importance of the knowledge 
to be gained outweigh the risks to the individual. The IRB also reviews the informed consent 
document associated with each study in order to ensure that the consent document accurately and clearly communicates the nature of the research to be done and its associated risks and benefits.
 
9.9.2 Protection of Privacy  
Patients will be informed of the extent to which their confidential health information generated 
from this study may be used for research purposes. Following this discussion, they will be asked 
to sign the HIPAA form and informed consent documents. The original signed document will 
become part of the patient’s medical records, and each patient will receive a copy of the signed 
document. The use and disclosure of protected health information will be limited to the individuals described in the informed consent document. 
  
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page [ADDRESS_734874] 22;373(17):1627- 39. 
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, 
Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, 
Spi[INVESTIGATOR_43942]. Nivolumab versus docetaxel in advanced squamous-cell non-small - cell lung cancer. 
N Engl J Med. N Engl J Med. 2015 Jul 9;373(2):123-35. 
Carbognin L, Pi[INVESTIGATOR_80046] S, Milella M, Vaccaro V, Brunelli M, Caliò A, Cuppone F, Sperduti I, 
Giannarelli D, Chilosi M, Bronte V, Scarpa A, Bria E, Tortora G. Differential activity of 
nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed 
death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. 
PLoS One. 2015 Jun 18;10(6):e0130142. 
Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and 
anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014 
Feb;124(2):687-95. 
Felip E, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Morán T, Astudillo J, Alonso G, Borro 
JM, González-Larriba JL, Torres A, Camps C, Guijarro R, Isla D, Aguiló R, Alberola V, Padilla 
J, Sánchez-Palencia A, Sánchez JJ, Hermosilla E, Massuti B; Spanish Lung Cancer Group. 
Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus 
surgery alone in early-stage non-small -cell lung cancer. J Clin Oncol. 2010 Jul 1;28(19):3138-45. 
Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko 
J, Sheikh NA, Sims RB, Frohlich MW, Small EJ. Activated lymphocyte recruitment into the tumor 
microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer 
Inst. 2014 Sep 24;106(11). 
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, 
Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman 
JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki 
GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators.Pembrolizumab for the 
treatment of non-small -cell lung cancer. N Engl J Med. 2015 May 21;372(21):2018-28. 
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, 
Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, 
Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of 
response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563-7. 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page [ADDRESS_734875] RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, 
Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-
Filhart M, Garon EB.Pembrolizumab versus docetaxel for previously treated, PD-L1- positive, 
advanced non-small -cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 
2016 Apr 9;387([ZIP_CODE]):1540-1550. 
McElnay P, Lim E. Adjuvant or neoadjuvant chemotherapy for NSCLC. J Thorac Dis. 2014 May;[ADDRESS_734876] 2:S224-7. 
Mesnage SJ, Auguste A, Genestie C, Dunant A, Pain E, Drusch F, Gouy S, Morice P, Bentivegna 
E, Lhomme C, Pautier P, Michels J, Le Formal A, Cheaib B, Adam J, Leary AF. Neoadjuvant 
chemotherapy (NACT) increases immune infiltration and programmed death- ligand 1 (PD-L1) 
expression in epi[INVESTIGATOR_76296] (EOC). Ann Oncol. 2016 Nov 17. pii: mdw625. [Epub 
ahead of print] 
Mok T, Wu Y-L, Watson PA, Zhang J, Rangwala RA, Lopes G. Phase 3 KEYNOTE-042 trial of 
pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients 
(pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 
2015;33(suppl): abstr TPS8105. 
Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, 
Chen C, Smith L, Espi[INVESTIGATOR_8614] G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pi[INVESTIGATOR_559398], Yearley 
JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW. Phase I Study of Pembrolizumab (MK-
3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer 
Res. [ADDRESS_734877] 1;21(19):4286-93. 
Robert C, Ribas A, Wolchok JD, Hodi FS,Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, 
Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus 
C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, 
Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipi[INVESTIGATOR_125]-
refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20;384(9948):1109-17. 
Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, 
Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, 
Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, 
Vonderheide RH, Minn AJ. Radiation and dual checkpoint blockade activate non-redundant 
immune mechanisms in cancer. Nature. 2015 Apr 16;520(7547):373-7. 
Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, Duret H, Yagita H, 
Johnstone RW, Smyth MJ, Haynes NM. Radiotherapy increases the permissiveness of established 
mammary tumors to rejection by [CONTACT_445672]. Cancer Res. 2012 Jul 1;72(13):3163-74. 
Yan F, Pang J, Peng Y, Molina JR, Yang P, Liu S. Elevated Cellular PD1/PD-L1 Expression 
Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells. PLoS One. 2016 Sep 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 31 of 82  9;11(9):e0162925. 
Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, 
Albesiano E, Pradilla G, Ford E, Wong J, Hammers HJ, Mathios D, Tyler B, Brem H, Tran PT, 
Pardoll D, Drake CG, Lim M. Anti-PD-1 blockade and stereotactic radiation produce long- term 
survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9. 
Zhang P, Ma Y, Lv C, Huang M, Li M, Dong B, Liu X, An G, Zhang W, Zhang J, Zhang L, Zhang 
S, Yang Y. The up-regulation of PD-L1 promotes the resistant response in non-small cell lung 
cancer patients with neo-adjuvant chemotherapy. Cancer Sci. 2016 Sep 1. doi: 10.1111/cas.[ZIP_CODE]. [Epub ahead of print] 
  
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 32 of 82  APPENDIX 1 ECOG Performance Status 
Grade  Description  
0 Normal  activity.  Fully  active,  able  to  carry  on  all  pre-disease 
performance without restriction.  
1 Symptoms, but ambulatory. Restricted in physically strenuous 
activity, but ambulatory and able to carry out work of a light or 
sedentary nature (e.g., light housework, office work).  
2 In bed <50% of the time. Ambulatory and capable of all self-care, but 
unable to carry out any work activities. Up and about more than 50% 
of waking hours.  
3 In bed >50% of the time. Capable of only limited self-care, confined 
to bed or chair more than 50% of waking hours.  
4 100% bedridden. Completely disabled. Cannot carry on any self-
care. Totally confined to bed or chair. 
5 Dead. 
* As published in Am. J. Clin. Oncol. Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., 
McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology 
Group. Am J Clin Oncol 5:649- 655, 1982. The Eastern Cooperative Oncology Group, Robert Comis 
M.D., Group Chair.  
 
  
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 33 of 82  APPENDIX 2 Common Terminology Criteria for Adverse Events V4.0 (CTCAE) 
 
The descriptions and grading scales found in the revised NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for adverse even t 
reporting. (http://ctep.cancer.gov/reporting/ctc.html ). 
  
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 34 of 82  APPENDIX 3 Response  Evaluation  Criteria  in  Solid  Tumors  (RECIST)  1.[ADDRESS_734878] version 1.1* will be used in this study for assessment of tumor response. While 
either CT or MRI may be utilized, as per RECIST 1.1, CT is the preferred imaging 
technique in this study. 
 
* As published in the European Journal of Cancer: 
 
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. 
Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, 
D. Lacombe, J. Verweij. New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan; 45(2):228-47. 
 
In addition, volumetric analysis will be explored by [CONTACT_133630]. 
  
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 35 of 82  APPENDIX 4 UCSF Policy/Procedure for Required Regulatory Documents for 
Single Site and Multicenter Investigator-Initiated Oncology Clinical Trials 
Purpose 
This policy defines the required Regulatory Documents for Single Site and Multicenter 
Investigator Initiated Oncology Clinical Trials at the Helen Diller Family Comprehensive Cancer 
Center (HDFCCC) for both IND and IND-exempt trials. 
Background  
The International Conference on Harmonization (ICH) Good Clinical Practices (GCP) Guidelines 
define Essential Regulatory Documents as those documents which individually and collectively permit evaluation of the conduct of a trial and the quality of data produced. These documents serve 
to demonstrate compliance with standards of GCP and with all applicable regulatory requirements. 
Filing essential documents in a timely manner can greatly assist in the successful management of 
a clinical trial. 
The Regulatory Documents will consist of electronic files in both iRIS and OnCore
®, as well as 
paper files in the Regulatory Binders for both the Coordinating Site and the Participating Site(s) 
in the HDFCCC Investigator Initiated Oncology Clinical Trials. 
Procedures  
Single Site (HDFCCC) Therapeutic Essential Regulatory Documents:   
Documents Filed in iRIS:  
• Current and prior versions of the Informed Consent Form(s) (ICFs). 
• IRB approvals for initial submission of application, all modifications, and continuing 
annual renewals. 
• Current and prior approved protocol versions. 
• Current IRB roster 
• Current and prior versions of the Investigator Brochure (IB). 
• Serious Adverse Event (SAE) Reports. 
• Subject diary and handouts (if applicable). 
• Single Patient Exception (SPE) Report(s) to IRB with Approval Letter(s) from IRB. 
• Protocol Violation (PV) Reports with acknowledgement from the IRB. 
Documents Filed in OnCore ®: 
• Package Insert (if the study drug is commercial). 
• Protocol signature [CONTACT_3264](s) with Pl signature(s) for all protocol versions. 
• Protocol Review Committee (PRC) approved protocols, protocol amendments and 
Summary of Changes (SOC) document. 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 36 of 82  • Screening/enrollment log. 
• Data and Safety Monitoring Committee (DSMC) monitoring reports. 
• DSMC dose escalation approvals with study status summary forms. 
• Case Report Form (CRF) completion manual. 
• Drug Destruction Standard Operating Procedure (SOP). 
• Completed Food and Drug Administration (FDA) 1572 document with Principal 
Investigator's signature. 
• For all Principal Investigators and Sub-Investigators listed on the FDA 1572, will 
need Financial Disclosure Forms, CVs, MD Licenses, and Staff Training Documents (i.e., Collaborative Institute Training Initiative (CITI), etc.). 
• As applicable, approvals for Biosafety Committee, Radiation Committee, and 
Infusion Center. 
• Serious Adverse Event (SAE) reports to IRB and Principal Investigator. 
• MedWatch reporting to FDA and Principal Investigator. 
• Drug Destruction Standard Operating Procedure (SOP). 
• For all laboratories listed on the FDA 1572, will need CUA certifications, CAP 
certifications, lab licenses, CV(s) and Medical License(s) of Lab Director(s), and laboratory reference ranges. 
Documents Filed in Regula tory Binder:  
• Delegation of Authority Log with signatures (to be scanned in OnCore once the trial 
is complete). 
Additional Essential Documents for Therapeutic Multicenter Trials for the Coordinating Center 
(filed in OnCore or Zip Drive):  
• Institutional Review Board (IRB) approval letters , IRB roster, Informed Consent 
Form (ICF), and Health Insurance Portability and Accountability Act {HIPAA) 
Consent Form for the Participating Site(s). 
• For all Principal Investigators and Sub-Investigators listed on the 1572 at the 
Participating Site(s), will need Financial Disclosure Forms , CVs, MD Licenses, and 
Staff Training documents (i.e. Collaborative Institute Training Initiative (CITI), etc.) (for investigational New Drug Application). 
• Site Initiation Visit (SIV) minutes and correspondence with the Participating Site(s). 
• As applicable, approvals for Biosafety Committee, Radiation Committee , and 
Infusion Center for the Participating Site(s). 
• Protocol Violations (PV) Reports to IRB with acknowledgement from IRB for Participating Site(s). 
• Single Patient Exception (SPE) Reports to IRB with IRB Approval Letters for 
Participating Site(s). 
• Drug Destruction Standard Operating Procedure (SOP) for the Participating Site(s) . 
• Data and Safety Monitoring Committee (DSMC) monitoring reports for the 
Participating Site(s). 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 37 of 82  • For all laboratories listed on FDA 1572, will need CUA certifications, CAP 
certifications, lab licenses, CVs and Medical License(s) of Lab Director(s), and 
laboratory reference ranges for the Participating Site(s). 
• Copy of the Data and Safety Monitoring Plan (DSMP) Monitoring Plan for all 
participating site(s) in Multicenter studies or Contract Research Organization (CRO) Monitoring Plan (if an outside CRO is used for the study). 
• Serious Adverse Event (SAE) forms submitted to the IRB for the Participating 
Site(s). 
Required Multicenter Essential Regulatory Document Checklist for Therapeutic  and Non -
Therapeutic Trials (For Start -Up Only): 
• See attached checklist(s). 
Required Essential Regulatory Documents for Single Site and Multicenter Therapeutic IND-
Exempt Studies (filed in OnCore):  
• For IND Exempt studies, the Essential Regulatory Documents for UCSF would 
include all documents in Section #1 of this policy. The Essential Regulatory 
Documents from the participating site(s) for Multicenter Trials when UCSF is the 
Coordinating Center would only include the signed protocol signature [CONTACT_3264], CV of 
the Pl, and the IRB approval letters. All other documents in Section #2 of this policy 
would be the responsibility of the Participating Site(s). 
Required Essential Regulatory Documents for Single Site Non -Therapeutic Studies (filed in 
OnCore):  
• For Single Site non-therapeutic trials , all Regulatory Documents in Section #1 of this 
policy are required except for: current and prior versions of the Investigator Brochure 
(IB), package insert (if the study drug is commercial), DSMC dose escalation 
approvals with study status summary forms, approvals for Biosafety Committee, 
Radiation Committee, and Infusion Center, and drug destruction SOPs. 
Required Essential Regulatory Documents for Multicenter Non -Therapeutic Studies (filed in 
OnCore):  
• For Multicenter non-therapeutic trials with UCSF as the Coordinating Site, all 
required Regulatory Documents listed above in Section #5 for Single Site non- therapeutic trials are required for the Coordinating Site. The only required Regulatory 
Documents from the Participating Site(s) will be: IRB approval letters, IRB roster, 
and ICF and HIPAA consent forms, the Delegation of Authority Log (with NIH or 
CITI human subject protection training certificates or GCP training certification), 
Protocol Violations and Single Patient Exception (SPE) reports to the IRB with 
supporting fax documentation (if applicable), Serious Adverse Event (SAE) forms 
submitted to both the IRB and the Principal Investigator, and the Data and Safety 
Monitoring Committee (DSMC) monitoring reports for the Participating Site(s). If 
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy   Page 38 of 82  applicable, a copy of the Data and Safety Monitoring Plan (DSMP) Monitoring Plan 
for all participating site(s) in Multicenter studies or Contract Research Organization 
(CRO) Monitoring Plan (if an outside CRO is used for the study) will be required. 
Alternate Procedures  
There are no alternate procedures to the HDFCCC policy for requirements for Essential 
Regulatory Documents for Multicenter Investigator-Initiated Oncology Clinical Trials . 
References  
• ICH Guidance for Industry: E6 Good Clinical Practice: Consolidated Guidance (current 
version). 
• International Conference on Harmonization: Good Clinical Practice: Consolidated 
Guideline (current version). 
• International Conference on Harmonization: Essential Documents for the Conduct of a 
Clinical Trial (current version). 
• 21CFR50 
• 21 CFR56.11 
• 45CFR46 
• 21 CFR312 
Required Regulatory Documents for Sub-Sites Participating in Therapeutic UCSF Investigator 
Initiated Multicenter trial 
Directions: Scan the documents in a zip drive and upload to OnCore. 
1572  
PI [INVESTIGATOR_14169]: 
• CV and Medical license 
• Financial disclosure form 
• NIH or CITI human subject protection training certification  
Laboratories: 
• CLIA &CAP and Lab Licenses 
• CV and Medical License of Lab Director 
• Laboratory reference ranges 
Local Institutional Review Board  
IRB Approval letter 
Reviewed/Approved documents 
• Protocol version date:    
• Informed consent version date:     
• Investigator Brochure version date:     
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy  Page 39 of 82  •HIPAA
Current IRB Roster
Other  
Delegation of Authority Log 
•Include NIH or CITI human subject protection training certificates or GCP
training certification
Pharmacy
•Drug destruction SOP and
Policy Protocol signaturepage  Executed subcontract
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy  Page 40 of 82  APPENDIX 5 Data and Safety Monitoring Plan for a Phase II or III Institutional 
Trial 
1. Oversight and Monitoring Plan
The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety 
Monitoring Committee (DSMC) is responsible for auditing data quality and participant safety for all HDFCCC institutional clinical trials.  A summary of DSMC activities for this trial includes:  
•Semiannual auditing (depending on trial accrual)
•Review of serious adverse events
•Minimum of biennial regulatory auditing
2. Monitoring and Reporting Guidelines
Investigators will conduct a continuous review of data and participant safety at monthly site 
committee meetings where the results of each participant’s treatment are discussed and documented in the site committee minutes.   
All institutional Phase II and III therapeutic trials are audited on a semiannual basis, with all data 
from twenty percent of the enrolled participants audited by [CONTACT_559427]/Auditor.  The assigned DSMC Monitor/Auditor will review no more than a total of 10 participant charts during the course of auditing this trial. DSMC Monitor/Auditors will send a follow-up report to the study team within 20 business days after the auditing visit is complete for the PI [INVESTIGATOR_80053] 20 business days.  An abbreviated regulatory review (i.e., reviewing protocol and consent versions, SAEs, PVs, DOA logs, 1572 forms, etc.) will occur at each participant monitoring review; however, a full regulatory review will occur on a biennially basis by [CONTACT_116799].
 
Auditing of all enrolled participants in these trials will be complete after 20% of enrolled participants have been audited through five cycles of treatment.  However, regulatory reviews of the trial, safety reviews (i.e., Serious Adverse Event (SAE) reviews and Protocol Violation (PV) reviews), and audit/inspection preparation (as applicable) will continue until the trial is closed by [CONTACT_1201].   
3. Review and Oversight Requirements
3.1 Adverse Event Monitoring
All Grade 3-5 adverse events (AEs), whether or not considered to be expected or unexpected and 
whether or not considered to be associated with the use of the investigational agent(s) or study procedure, will be entered into OnCore®, UCSF’s Clinical Trial Management System.   
UCSF Helen Diller Family Comprehensive Cancer Center 
Version date: 03/29/2021  Protocol CC#:  166520  
Phase II – Pembrolizumab +/ - Stereotactic Radiotherapy  Page 41 of 82  Adverse events are graded according to the Common Terminology Criteria for Adverse 
Events (CTCAE) as developed and revised by [CONTACT_80105] 
(CTEP) of the National Cancer Institute.  Adverse events are further given an assignment of attribution or relationship to investigational agent or study procedure.  Attribution categories are: 
• Definite – The adverse event is clearly related to the investigational agent(s) or
study procedure.
• Probable – The adverse event is likely related to the investigational agent(s) orstudy procedure.
• Possible – The adverse event may be related to the investigational agent(s) orstudy procedure.
• Unrelated – the adverse event is clearly not related to the investigational agent(s)or study procedure.
All Grade 3-5 adverse events entered into OnCore® will be reviewed on a monthly basis 
at the Site Committee meetings.  The Site Committee will review and discuss the selected 
toxicity, the toxicity grade, and attribution assignment. 
3.2 Serious Adverse Event Reporting 
By [CONTACT_108], an adverse event is defined as a serious adverse event (SAE) according to 
the following criteria: 
• Death.
• Life-threatening (i.e., results in an immediate risk of death).• Requires inpatient hospi[INVESTIGATOR_1081],• Permanent or significant disability/incapacity• Gives rise to a congenital anomaly/birth defect, or cancer, or any experience that
suggests a significant hazard, contraindication, side effect, or precaution that mayrequire medical or surgical intervention to prevent one of the outcomes listedabove.
• Event occurring in a gene therapy study.• Event that changes the risk/benefit ratio of a study.
• Any other event the Principal Investigator [INVESTIGATOR_559399] a significant hazard, contraindication, side effect, or precaution.
Serious adverse event reporting will be in accordance with all IRB regulations. For trials 
conducted under an investigational new drug (IND) application, the SAE will be reported in accordance with Code of Federal Regulation Title 21 Part 312.32 and will be reported on a Med Watch form.   
UCSF IRB website for guidance in reporting serious adverse events: 
����������������������������������������������������
������������������������ ������������� ������
������ ��������������������� ��������������������������� ������� ����������������������������������������
���������������������������������
����������������������������������
������������������������������������������������������������������������������������������
�������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������
�����������������������������������������������������������������������������������
��������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������
��� �����������������������������
�����������������������������������������������������������������������������������������������������������������������������������������������������������������������������
��������������������������������������������������������������������������������������������
������������������������������������������������������������������������������������������������������������������������������������������������������������
���������������������������������������������������������������������������������������
����������������������������������������������������������������������������������������������������������������������������������������������������������������������������
�����������������������������������������������
�������������������������������
����������
��������������������������������������
�����������������������������
��������
�����������
�����������������������